Effects of Dietary Calcium and Fasting on Osteoclast Recession and Recruitment in Calcium Deficient Rats by Wright, Kenneth R.
Loma Linda University 
TheScholarsRepository@LLU: Digital Archive of Research, 
Scholarship & Creative Works 
Loma Linda University Electronic Theses, Dissertations & Projects 
12-1992 
Effects of Dietary Calcium and Fasting on Osteoclast Recession 
and Recruitment in Calcium Deficient Rats 
Kenneth R. Wright 
Follow this and additional works at: https://scholarsrepository.llu.edu/etd 
 Part of the Anatomy Commons, and the Physiology Commons 
Recommended Citation 
Wright, Kenneth R., "Effects of Dietary Calcium and Fasting on Osteoclast Recession and Recruitment in 
Calcium Deficient Rats" (1992). Loma Linda University Electronic Theses, Dissertations & Projects. 974. 
https://scholarsrepository.llu.edu/etd/974 
This Thesis is brought to you for free and open access by TheScholarsRepository@LLU: Digital Archive of 
Research, Scholarship & Creative Works. It has been accepted for inclusion in Loma Linda University Electronic 
Theses, Dissertations & Projects by an authorized administrator of TheScholarsRepository@LLU: Digital Archive of 




EFFECTS OF DIETARY CALCIUM AND FASTING
ON OSTEOCLAST RECESSION AND RECRUITMENT
IN CALCIUM DEFICIENT RATS
by
Kenneth R. Wright
The osteoclast, a multinucleated giant cell, has as its role the resorption of 
bone matrix with consequent release of calcium. The osteoclast is thought to 
derive from a pluripotent stem cell which also gives rise to monocytes and 
macrophages. The development, activation, and inhibition of osteoclasts are 
influenced by a number of systemic and local factors. The release of these 
factors is influenced by changes in the dietary status of the animal. Calcium 
deficiency is known to stimulate the recruitment and activity of large numbers of 
osteoclasts. These osteoclasts can subsequently be inhibited by increasing dietary 
calcium intake. Disappearance of osteoclasts from the endosteum of long bones 
is complete after three days, but it is not known whether this phenomenon is 
gradual or whether there is a dietary calcium threshold that must be reached to 
cause complete osteoclast inhibition.
This study examines changes in osteoclast morphology in calcium deficient 
rats following calcium supplementation and fasting. In rats which had been given 
a calcium-deficient diet 7 days, 12 hours of ad libitum calcium supplementation 
caused changes in osteoclast morphology indicating a reduction in osteoclast 
activation. These morphological changes were reversed when calcium 
supplementation was followed by a 12-hour fast.
In another experiment, generalized nutritional deficiency (i.e. fasting) was 
compared with calcium deficiency. Forty-eight hours of fasting in normal rats 
caused a decrease in the osteoblast area fraction and an increase in the resting­
cell area fraction; the osteoclast area fraction was unaffected. Forty-eight hours 
of calcium deficiency, however, increased the osteoclast area fraction and 
decreased the resting area fraction, while the osteoblast area fraction did not 
change. These results suggest that whereas fasting conserves plasma calcium by 
reducing the osteoblast area fraction and thus bone formation, calcium deficiency 
maintains plasma calcium by increasing osteoclastic bone resorption. A final 
experiment showed that osteoclasts that have been inhibited by 48 hours of 
calcium supplementation did not return to pre-inhibition levels of activity after 48 
hours of calcium deficiency. It was concluded that osteoclasts are under dynamic 
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In recent years, much attention has been given to the study of bone diseases 
such as Paget’s Disease, osteopetrosis, and especially osteoporosis. With an 
increasing elderly population in America, the cost of caring for victims of 
osteoporosis is rapidly growing. Much effort is being spent pursuing new 
medications that will alter bone metabolism in such a way as to decrease bone 
loss. The loss of bone in osteoporosis is thought to result from an imbalance 
between bone resorption and bone formation. These two processes occur 
concurrently in normal individuals, but when resorption and formation are 
uncoupled, and resorption occurs to a greater extent than formation, the loss of 
bone mass results. To effectively control bone resorption, the mechanism by 
which it occurs must be understood. This involves a thorough knowledge of the 
biology of the bone-forming and bone-resorbing cells, the osteoblasts and the 
osteoclasts. This study focuses on the activity of the osteoclast.
light microscopic examination of one nm sections of rat tibial diaphysis 
stained with toluidine blue reveals three cell types making up the endosteum, the 
layer of cells covering the bone surface that forms the boundary of the marrow 
cavity (see Appendix C). These endosteal cell types include the osteoblast, the 
bone lining cell or resting osteoblast, and the osteoclast. Osteoblasts and bone 
lining cells are believed to be essentially the same cell type at different levels of 
activation. The lining cell is a flattened, elongated cell, whereas the osteoblast is 
more cuboidal, with a distinct negative-staining Golgi region when stained with
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toluidine blue. Both of these cell types are mononucleated. The osteoclast is 
normally the only multinucleated giant cell found in the endosteum.
The osteoclast is the cell responsible for bone resorption. The ultrastructure 
of the cell reveals machinery geared for high energy expenditure and osteolytic 
activity. The cytoplasm is especially rich in mitochondria, lysosomes, and 
vacuoles, and is amply stocked with Golgi and free ribosomes, and some rough 
endoplasmic reticulum (see Holtrop and King 1977). The active cell 
demonstrates a clear polarity. The plasma membrane adjacent to the bone 
surface is greatly folded forming a characteristic "ruffled border". Surrounding 
this ruffled border and forming a "sealing zone" is an area of cytoplasm devoid of 
organelles termed the "clear zone". An osteoclast that has been actively resorbing 
bone for a period of time sits in a concave excavation of bone commonly called a 
Howship’s lacuna. Due to the degree of vacuolization and the sparser rough 
endoplasmic reticulum, the osteoclast’s cytoplasm stains lighter, with a more 
"frothy" appearance, than either the osteoblast or the bone lining cell. At high 
magnification, the ruffled border and clear zone are visible with light microscopy. 
Thus, the osteoclast is easily distinguishable from the other endosteal cells at the 
light microscopic level.
Osteoclast Origin
Several theories have been proposed in an effort to explain the origin of the 
osteoclast. One theory, now abandoned, stated that the progenitor cell of bone 
osteoblasts and osteoclasts was a sessile connective tissue cell. A second
3
hypothesis for which supporting evidence is lacking proposed that osteoclasts 
derive from liberated osteocytes or chondrocytes. Current evidence, some of 
which will be presented below, suggests that the osteoclast progenitor is a 
hemopoietic stem cell, that it has a separate lineage from the osteoblast, and that 
it shares a common ancestor with the monocyte.
One of the earliest studies into the origin of the osteoclast was carried out by 
Fischman and Hay (1962) who used a regenerating newt limb model to show that 
osteoclasts are post-mitotic cells deriving from a leucocyte source. Tritiated 
thymidine injections were given 1-28 days after limb amputation, and animals 
were sacrificed 3 hours after thymidine injection. None of the osteoclasts in the 
tissue samples taken from these animals had labelled nuclei, indicating that no 
DNA synthesis had occurred within these cells. In a second experiment, tritiated 
thymidine was given at 5, 10 and 15 days after amputation, and while 
mesenchymal cells in the regenerating limb were found to be labelled, the 
osteoclasts never were, providing evidence that osteoclasts do not derive from 
mesenchymal cells. Finally, animals were labelled one day before amputation 
and followed for up to 28 days after amputation. It was found that labelled 
monocytes appeared in the regenerating limbs, with labelled osteoclasts appearing 
afterward. The authors concluded that osteoclasts derive from a blood-borne
precursor cell, which they felt to be the monocyte.
Several groups provided evidence that osteoclasts and osteoblasts derived 
from separate lineages. Gothlin and Ericsson (1973) joined pairs of rats by
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parabiosis, subjected one rat to whole-body irradiation to destroy hemopoietic 
stem cells, and shielded the other animal from the radiation. The shielded 
animal was given tritiated thymidine. In the shielded animal, many cell types 
including fibroblasts, chondroblasts, preosteoblasts and osteoblasts, as well as cells 
of the mononuclear phagocytic system (MPS), were labelled with the tritiated 
thymidine. However, in the irradiated animal only MPS cells were labelled 
showing that these cells had an extraskeletal origin, and that their origin was 
different from that of the osteoblast lineage. Miller et al. (1977) injected rats 
with ethane-1-hydroxy-1,1-diphosphonate (EHDP) over a period of six days, then 
gave 3 [H]-thymidine injections at 8-hour intervals for 40 hours. They found that 
EHDP caused an increase in the numbers of both osteoclasts and osteoclast
nuclei, but the number of osteoprogenitor cells remained unchanged or 
decreased. While EHDP increased the numbers of osteoclasts, the rate of bone
resorption was decreased. This led them to the conclusion that osteocytes, which 
would be released by osteoclastic bone resorption, could not be major 
contributors to the formation of osteoclasts, since few osteocytes were being 
released. Jotereau and LeDouarin (1978) grafted chick bone primordia onto 
Japanese quail chorio-allantoic membrane. Chondrocytes, osteocytes and 
osteoblasts that developed in the bone rudiment had chick-like nuclei, but 
myeloid and erythroid cells and osteoclasts had quail nuclei, again showing the 
extra-osteal origin of the osteoclast, and a separate origin for osteoclasts and 
osteoblasts. Kahn and Simmons (1975) had earlier used the quail/chick chimera
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model to show that osteoclasts arise from the fusion of mononuclear
hematogenous cells.
Yabe and Hanaoka (1985) later raised questions about the hemopoietic 
origin of the osteoclast. They also used quail-chick chimera, but arrived at 
different conclusions than Kahn and Simmons, and Jotereau and LeDouarin. In a
first experiment, they grafted quail limb buds onto chick CAM, and they found
that the osteoblasts and osteocytes which formed in the limb bud had quail-like 
nuclei, but the osteoclasts displayed either quail-type, chick-type or mixed-type 
nuclei. They next grafted either viable or devitalized pieces of Dunn 
osteosarcoma onto the CAM. In both cases, bone formation was induced, with
osteoblasts and osteoclasts being formed. They reasoned that these cells couldn’t 
have originated from devitalized osteosarcoma cells, so they must have come
from the CAM. In their third experiment, they again used quail limb buds, but
this time enclosed in a diffusion chamber, so that no cells could enter. The 
chambers containing the limb buds were grafted onto the CAM, and after 5 days 
incubation, PTH was administered, followed by 3 to 48 hours incubation time. 
Osteoclasts were found in those specimens that had received PTH and then went 
48 hours before fixation. The authors concluded that the osteoclasts had to have
originated from the mesenchymal cells (perichondrium) of the limb buds. Thus 
they assumed that mesenchymal cells give rise to osteoclasts.
The majority of studies, however, supported the idea of the myelogenic origin 
of the osteoclast. When Walker (1975) transplanted spleen or marrow cells from
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normal mice to irradiated osteopetrotic mice, the osteopetrosis was cured. Marks 
and Schneider (1978) used this same model but by using the Ficoll-Hypaque 
method to separate various cells fractions from spleen or thymus cells, they 
proposed that it was the mononuclear cell fraction that gave origin to the 
osteoclast. Coccia et al. (1980) reported reversing human osteopetrosis by 
transplanting marrow from a male HLA identical sibling to a female patient. 
Evidence for the myelogenic origin of the osteoclast lay in the fact the osteoclasts 
in the cured female patient had fluorescent Y bodies upon staining with 
quinacrine, indicating that their precursors came from the marrow cells of the 
male donor. Sorell et al. reported similar results (1981). Ko and Bernard 
showed that the addition of mononuclear marrow cells to fetal mouse calvarial
cultures was necessary to produce osteoclasts. Burger et al. (1982) found that 
osteoclasts appeared and 45 Ca was released in embryonic long bone cultures only 
when marrow or embryonic liver cells were added. Studies by Ibbotson et al.
(1984), Fuller and Chambers (1987), Suda et al. (1992), Hattersley et al. (1991), 
and others (Takahashi et al. 1988b; Akatsu et al. 1989; Akatsu et al. 1989b;
Akatsu et al. 1991) also confirmed the myelogenic origin of the osteoclast.
Although several studies showed that osteoclasts are not derived from 
macrophages (Fuller and Chambers 1987; Kurihara et al. 1990), research 
indicates a common origin for MPS cells (Athanasou et al. 1988; Hattersley et al.
1991).
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Research is currently investigating stages of development of the osteoclast 
precursor into the mature osteoclast. An example is a study by Helfrich, 
Mieremet, and Thesingh (1989) showing that whereas the mature osteoclast stains 
positively for tartrate-resistant acid phosphatase (TRAP), early precursors are not
TRAP+.
In summary, the current understanding of osteoclast origin is that the 
multinucleated osteoclast is formed by the fusion of mononuclear precursor cells 
which come from a different lineage than the osteoblast, and that they have a 
common myelogenic ancestor with the monocyte and macrophage.
Factors Involved in Osteoclast Recruitment. Activation or Inhibition
The regulation of osteoclast activity is a complex phenomenon involving both 
systemic and local factors such as hormones, cytokines and growth factors. A 
great amount of research is currently being done to elucidate the roles and 
interactions of these substances. The following is a brief summary of some of the 
findings having to do with factors influencing osteoclast activity.
Systemic Hormones 
Parathyroid hormone (PTH)
Parathyroid hormone is an active agent in the regulation of blood calcium 
levels. Early studies of the hormone revealed seeming contradictions in its role 
in bone metabolism. Bauer, Aub and Albright (1928) found a reduction in long 
bone trabeculae when daily injections of parathyroid extract (PTE) were given to
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rabbits and cats, and PTE given to growing kittens caused a diminution in long 
bone length but an increase in the number of trabeculae. Selye (1932) showed 
that high doses (overdoses) of PTE stimulated bone resorption (osteitis fibrosa) by 
osteoclasts, but that this phenomenon was followed by a disappearance of 
osteoclasts, with an increase in osteoblast numbers and bone formation, as was 
also later shown by Burrows (1938). A low dose of PTE brought about increased 
osteoblast numbers and bone formation, without the preceding bone resorption.
Shelling, Asher, and Jackson (1933) confirmed this finding that a low dosage of
PTH increases bone formation, while high doses cause resorption. This 
difference in the effects produced by PTH at low and high doses probably 
accounted for the results obtained by Tam et al. (1982), who found that daily 
injections of bovine PTH (bPTH) into rats increased the bone apposition rate and 
a net increase in trabecular bone (confirmed by Mosekilde et al. 1991), whereas 
continuous infusion of bPTH into rats caused an increase in both the formation
and resorption areas with a net decrease in trabecular bone volume.
Baraicot (1945) used grey-lethal mice to show that high doses of PTE 
inhibited osteoblasts and increased bone loss, and that low doses of PTE 
stimulated osteoblastic activity, resulting in greater bone deposition. He later 
developed a system of transplanting parathyroid glands to pieces of parietal bone 
in mice, in order to determine the effects of the direct action of PTH on bone 
(Baraicot 1948). The bone pieces, with attached parathyroid glands, were grafted 
to a cerebral hemisphere of a litter-mate, and after 12-14 days, active osteoclastic
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bone resorption resulted. Chang (1951) confirmed Barnicot’s findings when, after 
transplanting parathyroid glands to parietal bones subperiosteally, he reported 
marked resorption of parietal bone around the grafts with minimal new bone 
deposition.
Later in vitro studies (Gaillard 1955; Raisz 1965) showed an increase in the 
number of osteoclasts and in bone resorption under the effects of PTE or PTH. 
Numerous studies have since shown increases in numbers of osteoclasts and
osteoclast nuclei (Holtrop et al. 1979; Baron and Vignery 1981), as well as 
increases in osteoclastic activity as evidenced by changes in morphology (Holtrop 
et al. 1979; Miller, Bowman, and Myers 1984; Pandalai and Gay 1990) brought 
about by PTH. Data from Lorenzo et al. (1983) suggest that PTH acts on 
already-differentiated osteoclasts or osteoclast precursors, but does not induce 
DNA synthesis in undifferentiated osteoclast precursors. Recent studies (Somjen 
et al. 1991; Fenton et al. 1991) suggest that differences in the effects of PTH on 
bone (stimulation of formation vs resorption) might be due in part to the action 
of fragments of PTH or PTH-related peptide (PTHrP), since it was shown that 
certain of these fragments can induce formation while others cause resorption. 
The insulin-like growth factors (IGF) might also play a role in the induction of 
bone formation by PTH. IGF-I has been found to stimulate bone formation
(Spencer et al. 1991), and Linkhart and Mohan (1989) have shown that PTH
stimulates the release of IGF-I and IGF-II from osteoblasts in neonatal mouse
calvaria cultures.
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PTH secretion is controlled by blood calcium levels (de Winter and Steendijk
1975; Thompson, Baylink and Wergedal 1975; Toffaletti, Cooper and Lobaugh 
1991). The mechanism by which PTH produces its effects is only poorly
understood, but current thinking is that PTH ( as well as other factors) directly 
stimulates osteoblast-lineage cells, which then exert some influence on osteoclasts,
either by production of some soluble "coupling factor" (Rodan and Martin 1981; 
Shupnik and Tashjian 1982; McSheehy and Chambers 1986; Kahn and Partridge 
1987; McSheehy and Chambers 1987; Perry et al. 1987; Thomson, Mundy and 
Chambers 1987; Fuller, Gallagher, and Chambers 1991; Hoekman et al. 1991; 
Cheng, Shen, and Peck 1991; Li et al. 1991), or by direct cell/cell contact 
(Yamashita et al. 1990; Akatsu et al. 1991). Osteoblasts are known to produce a 
number of factors that affect osteoclast behavior (Heath et al. 1984; Gutierrez, 
Mundy and Katz 1984; Thomson, Saklatvala and Chambers 1986; Takahashi et al. 
1991). Most PTH binding studies have shown that osteoblast-lineage cells are the 
only bone cells with PTH receptors (Silve et al. 1982; Rouleau, Warshawsky and 
Goltzman 1986; Rouleau, Mitchell and Goltzman 1990); although several other 
studies (Rao, Murray and Heersche 1983; Teti, Rizzoli, and Zambonin Zallone 
1991; Agarwala and Gay 1992) indicate that osteoclasts might also possess PTH
receptors.
PTH has been shown to produce a number of effects in bone cells. PTH 
stimulates an increase in adenyl cyclase and cyclic AMP (cAMP) activity (Chase,
Fedak and Aurbach 1968; Crisp, Mcguire-Goldring and Goldring 1984).
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Dibutyryl cAMP added to chick tibia cultures increased the effects of PTH 
(Pandalai and Gay 1990). Peck, Kohler and Barr (1981) found Ca2* to be a
positive effector of the cAMP response of isolated bone cells to PTH.
Release of acid hydrolases (Vaes 1968), increase in acid phosphatase activity 
and hyaluronate synthesis (Luben, Wong and Cohn 1976), and increased RNA 
synthesis (Bingham, Brazell and Owen 1969) have been shown in osteoclasts 
under the influence of PTH. In osteoblasts, PTH has been shown to decrease 
alkaline phosphatase, citrate decarboxylation and prolyl hydroxylase activity. PTH 
has also been shown to stimulate plasminogen activator production in both 
osteoclasts and osteoblasts. And finally, Peterson, Heideger and Beach (1985) 
found that PTH increased the measured electrical potential difference across the 
periosteal layer in embryonic chick calvaria in vitro.
Vitamin P
l,25(OH^cholecaldferol [l,25(OH^Dj], the most active form of vitamin D, is
known to be involved in the control of calcium homeostasis and to influence
osteoclast activity. The hormone has been shown to increase calcium absorption 
by the gut (Garabedian et al. 1974; Nemere, Yoshimoto, and Norman 1984; 
Kumar 1986) and is implicated in the regulation of renal calcium and phosphate 
excretion (Reichel, Koeffler, and Norman 1989). l,25(OH)^Bj has also been 
found to play a role in the control of PTH secretion (Russell, Lettieri, and 
Sherwood 1986; Reichel, Koeffler, and Norman 1989).
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Numerous studies have shown that l,25(OH)^Dj causes increases in the 
number and size of osteoclasts, and in the number of osteoclast nuclei as well as 
in ruffled border and clear zone area (Holtrop and Raisz 1979; Holtrop et al. 
1981; Pharoah and Heersche 1985; Roodman et al. 1985; Grise et al. 1990; 
Takano-Yamamoto et al. 1992). Hattersley and Chambers (1989) found that Dj 
increased the number of CT-receptor-containing cells and the amount of bone 
resorption at the same time. They concluded that Dj induces terminal 
differentiation of osteoclast precursors. Other authors agree that the hormone 
increases bone or dentine resorption (Holtrop and Raisz 1979; Shiina et al. 1986; 
McSheehy and Chambers 1987; Takahashi et al. 1988). Grise et al. (1990) were 
able to show that l,25(OH^D3 increased TRAP and tartrate-resistant acid 
ATPase (TraATPase) activity in osteopetrotic (os) rabbits.
Vitamins D and A have been found to increase collagenase production and 
to reduce collagenase inhibitor in cultured mouse calvaria, thus changing the 
collagenase/inhibitor ratio in favor of the active enzyme (Sellers, Meikle, and 
Reynolds 1980). Heath et al. (1984) later reported that 1^5(OH^E)^, as well as 
PTH and PGI^, stimulates the secretion of collagenase by osteoblastic cells in 
mouse calvarial culture. Baylink et al. (1970), and later Underwood and DeLuca 
(1984), found that vitamin D stimulates bone growth and mineralization indirectly 
by elevating plasma calcium and phosphorus levels. The 24R,25(OH)^ form of 
the vitamin was found to inhibit ovariectomy-induced bone turnover in dogs
(Nakamura et al. 1992).
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Receptors for l,25(OH)^Dt3 have been found in osteogenic sarcoma cells 
(Manolagas, Haussler, and Deftos 1980), in osteoprogenitor cells and osteoblasts 
(Narbaitz et al. 1983), and in monocytes but not in osteoclasts (Merke et al.
1986).
Estrogen
The decrease in estrogen production at the time of menopause is known to 
contribute to me bone loss associated with osteoporosis. Estrogen has been 
shown to play a role in maintaining bone mass. This is at least in part due to an 
inhibition of osteoclastic bone resorption (Oursler et al. 1991; Hashimoto et al.
1991; Liu and Howard 1991; Oursler et al. 1991b; Chow et al. 1992). This was
found to be true in post-menopausal women, where it was shown that the 
administration of two different estrogen compounds reduced the urinary excretion 
of calcium and hydroxyproline (indicators of bone resorption) (Selby et al. 1985). 
These changes were not accompanied by any changes in plasma CT or PTH 
levels, suggesting that estrogen inhibits bone resorption without the intervention 
of calcium-regulating hormones. However, Brunner, Schraner, and Wild (1992) 
reported that progesterone (and testosterone) provoked an increase in nuclear 
and cell volume and in cell surface, as well as increases in the areas of rough 
endoplasmic reticulum and the Golgi complex in rat parathyroid glands, indicating 
that sex steroids might modulate parathyroid secretion.
Several mechanisms for the reduction of bone resorption by estrogen have 
been proposed. Oursler et al. (1991) found that estrogen increased nuclear
14
protooncogene mRNA levels in osteoclasts. Liu and Howard (1991) found that
t
estradiol reduced the osteoclast/mm surface length and increased the number of 
osteoclasts found in the marrow space and separated from bone in female 
weanling mice. They also reported that estradiol brought about a decrease in 
osteoclast size, changes in osteoclast morphology, and an increase in the numbers 
of TRAP+ fragments in the marrow space. Oursler et al. (1991b) showed that 
17-6 estradiol inhibited bone resorption via its stimulation of TGF-6 production.
Estrogen has also been shown to increase bone formation. Hashimoto et al. 
(1991) showed that estradiol could preserve ectopically-induced bone in mice by 
enhancing bone formation as well as by inhibiting resorption. Liu and Howard 
(1991) showed that while estradiol was decreasing osteoclast size and numbers, it 
also increased the numbers and size of osteoblasts both in trabeculae and along 
the diaphysis of long bones. Chow et al. (1992) showed that exogenous estrogen 
could increase bone formation in resorption-inhibited, ovariectomized rats.
Estrogen receptors have been found both in cells of osteoblast lineage
(Ohashi, Kusuhara and Ishida 1991) and in osteoclasts (Pensler et al. 1990; 
Oursler et al. 1991).
Calcitonin (CT)
Calcitonin was so named because it was identified by Harold Copp as a 
hormone that controlled blood calcium "tone". Much recent evidence has shown
that one primary function of calcitonin is to inhibit bone resorption (Friedman, 
Au and Raisz 1968; Wener, Gorton, and Raisz 1972; Eilon and Raisz 1978;
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Wronski et al. 1991). This is thought to happen through an inhibition of 
osteoclast formation and activity (Kallio, Garant, and Minkin 1972; Lucht 1973; 
Holtrop, Raisz and Simmons 1974; Feldman, Krieger and Tashjian 1980; 
Klaushofer et al. 1989; Hunter, Schraer and Gay 1989; Matthews 1992). Eilon 
and Raisz (1978) showed that calcitonin, as well as cortisol and colchicine, 
blocked the PTH- and PG^-stimulated release of lysosomal enzymes and of ^Ca 
in fetal rat long bone culture. Calcitonin was shown to prevent a decrease in 
bone volume, and to decrease indices of bone turnover in ovariectomized rats 
(Wronski et al. 1991). The hormone has also been shown to block the 
development of ruffled border that is induced by IL-2 and PGEg. Calcitonin 
secretion was found to be stimulated by an increase in plasma calcium, and shows 
a circadian pattern of secretion (Hillyard et al. 1977). Calcitonin has also been 
found to increase cell proliferation and alkaline phosphatase activity in osteoblast­
like cells (Farley et al. 1991).
Calcitonin binding has been demonstrated on osteoclasts (Warshawsky et al. 
1980; Rao et al. 1981; Nicholson et al. 1986; Eliam et al. 1988) and on osteoclast 
precursors (Nicholson et al. 1986; Taylor et al. 1989; Minkin and Yu 1991).
There are also CT binding sites in the kidney (Warshawsky et al. 1980). Rao et 
al. (1981) reported sCT binding to periosteal osteoblasts, as well as to striated 
muscle fibers and erythrocytes.
When calcitonin is administered over a period of days, the hormone suddenly 
seems to lose its ability to inhibit osteoclastic activity. This phenomenon is
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termed "escape”. Wener, Gorton and Raisz (1972) reported that CT inhibited 
PTH- or 25 (OH)D3-induced bone resorption in vitro, but after several days of 
treatment CT lost its inhibitory effect. They found that escape could be 
prevented or delayed by decreasing the concentration of calcium or phosphorus in 
the culture medium. Feldman, Krieger, and Tashjian (1980) suggested that 
escape was due to the fact that calcitonin inhibits the fusion of preexisting 
mononuclear osteoclast precursors with existing osteoclasts, thus making 
osteoclast recruitment dependent on the fusion of newly formed postmitotic 
precursor cells - a slow process which could account for the lag time in osteoclast 
activity followed by "escape". Klaushofer et al. (1989) noted the escape 
phenomenon in a cultured neonatal mouse calvaria system. They found that 
escape occurred coincidentally with the appearance of small active osteoclasts, 
and suggested that escape occurred when a new batch of osteoclasts differentiated 
to take the place of the already-existing osteoclasts that had been inhibited. This
would agree with the theory proposed by Feldman, Krieger, and Tashjian (1980).
Other hormones
Other hormones such as growth hormone (Takagi et al. 1992) and tri­
iodothyronine (Allain et al. 1992) have been shown to affect osteoclastic activity, 
but their roles in osteoclast function have not yet been thoroughly examined. 
Paracrine Regulators of Osteoclast Function 
Colony Stimulating Factors
The development and differentiation of hemopoietic stem cells into specific
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cell lineages has been intensively studied. It has been recognized that 
’’hemopoietic cells are intrinsically incapable of unstimulated cell division” 
(Metcalf 1985), but certain glycoproteins are capable of stimulating development 
of hemopoietic cell colonies in vitro. These substances have been called colony 
stimulating factors. Granulocyte-macrophage colony-stimulating factor (GM- 
CSF) and macrophage colony-stimulating factor (M-CSF) appear to be involved 
in osteoclast development and activity. However, there is debate over the role of 
these factors: some authors report stimulation of osteoclast development with 
these factors, while others report inhibition.
Shinar, Sato, and Rodan (1990) found that generation of osteoclasts in
culture was inhibited by GM-CSF and M-CSF (as well as by IL-3), but not by 
granulocyte-CSF (G-CSF), IL-6 or leukemia inhibitory factor (LEF). The authors
suggested that the three factors causing inhibition of osteoclast formation might 
either be diverting a common precursor cell to some other developmental 
pathway and thus reducing its availability for the formation of osteoclasts, or that 
the cells generated in response to these factors, especially macrophages, might 
release cytokines which inhibit the formation of osteoclasts. Hattersley et al. 
(1991b) reported that M-CSF in normal (as opposed to osteopetrotic) mouse 
spleen cell cultures stimulated macrophage production but inhibited osteoclast 
formation. However, in spleen cell cultures from osteopetrotic op/op mice, a 
mutant strain that lack osteoclasts, M-CSF restored osteoclast production.
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Takahashi et al. (1991) cocultured spleen cells from op/op mice with 
osteoblast cells from calvaria of normal mice. They found that TRAP+ 
multinucleated cells (MNC) formed in the presence of Dj. But when osteoblasts 
from op/op mice were cocultured with spleen cells of normal mice, no TRAP+ 
MNCs formed unless M-CSF was added. These results suggest that the defect in 
op/op mice is the lack of production of M-CSF by osteoblasts, and that M-CSF 
from osteoblasts is needed to produce osteoclasts. In a similar experiment, 
Kodama et al. (1991) established a clonal stromal cell line that supports 
hemopoiesis with neonatal op/op mouse calvaria. Adding M-CSF to the 
coculture increased the number of cells identified as macrophages by the authors. 
TRAP+ cells appeared when both M-CSF and Dtj were added and when stromal 
cells were in contact with the op/op cells.
Marks and colleagues used a different osteopetrotic mutation, the toothless 
(tl) rat, to demonstrate the effects of CSF. In one study (Marks et al. 1992) it 
was found that injecting CSF-1 into rats during the period from birth to 6 weeks 
of age reduced osteopetrosis, increased body weight and brought about tooth 
eruption and the induction of large numbers of osteoclasts and macrophages. In 
another study (lizuka et al. 1992), the success of CSF-1 in stimulating tooth 
eruption in tl rats was found to be inversely related to the age at which treatment 
began. Staining by TRAP and TraATPase was found to be reduced or negligible 
in untreated tl rats, heavy in normal rats and of intermediate intensity in
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CSF-1 treated tl rats. Treated rats were also shown to have a greater number of
osteoclasts on alveolar bone than untreated animals.
Corboz et al. (1992) reported that human recombinant M-CSF stimulates 
bone resorption in vitro only when the resorption is dependent on the generation 
of new osteoclasts. M-CSF does not appear to stimulate mature osteoclasts.
Cytokines
The cytokines are soluble products produced by certain cells (lymphocytes, 
osteoblasts, etc.) that influence growth, morphology and other specific functions of 
the same or other cells in their local environment (Krane, Goldring and Goldring 
1988). Many of these products have been shown to affect osteoclast development 
and activity.
Interleukins (IL)
One of the most important of the cytokines in regulating osteoclast activity is 
IL-1, a substance produced by monocytes and macrophages.
Most studies agree that IL-1 increases bone resorption (Gowen and Mundy 
1986; Thomson et al. 1986; Akatsu et al. 1991; Nguyen et al. 1991). Pfeilschifter 
et al. (1989) and Akatsu et al. (1991) reported increases in the number of 
osteoclasts or MNCs with IL-1. Several studies show that osteoblasts are
necessary to stimulate BL-l-induced osteoclast formation and bone resorption 
(Thomson et al. 1986; Akatsu et al. 1991), but Nguyen et al. (1991) reported that 
IL-1 caused a decline in serum osteocalcin levels and in the mineral apposition
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rate (which are measures of osteoblastic activity). Gowen and Mundy (1986) 
found that cyclooxygenase inhibitor did not inhibit IL-l-stimulated bone 
resorption, implying that prostaglandins do not mediate IL-1 activity, but Akatsu 
et al. (1991) found that the increase in osteoclast numbers and in bone resorption 
could be inhibited by indomethacin, indicating that prostaglandin synthesis is 
involved in IL-1 activity. Similarly, Linkhart and MacCharles (1992) reported 
that indomethacin inhibits the IL-l-stimulated release of IGF-I and Ca from
neonatal mouse calvaria in culture, showing that IL-1 acts via prostaglandin 
synthesis. Several studies (Ikeda et al. 1988; Evans, Bunning, and Russell 1990) 
reported that IL-lB caused an increase in PGE^ production by osteoblast-like 
cells.
IL-4 has been reported by Shioi et al. (1991) to inhibit the formation of 
osteoclasts in cocultures of bone marrow cells and stromal cells. This inhibitory 
effect of IL-4 was shown to be antagonized by an IL-4 monoclonal antibody.
ILr6 is another interleukin that has been shown to stimulate MNC formation
in marrow culture (Roodman et al. 1992). It was found both in the marrow 
plasma and blood serum of patients with Paget’s disease.
Transforming growth factors (TGF)
Two types of transforming growth factors, alpha and beta, have been 
identified as affecting bone cell activities. TGF-alpha has been found to induce 
bone resorption (Ibbotson et al. 1985) by increasing the proliferation of osteoclast 
precursors (Takahashi et al. 1986) and by stimulating PGEg production (Tashjian
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et al. 1985). It has also been shown that TG¥-alpha has additive effects with 
PTH or PTHrP in stimulating bone resorption and adenylate cyclase activity in 
osteoblast-like cell line cultures (Rosol et al. 1991).
The role of TGF-6 seems more complex. Like TGF-alpha, TGF-6 has been 
shown to increase bone resorption (and PGI^ production) in some circumstances 
(Tashjian et al. 1985). Mundy and Bonewald (1990) attribute this increase in 
bone resorption to the stimulation of prostaglandin synthesis by TGF-B, with the 
prostaglandin then being the stimulating agent for bone resorption. Some studies 
have also shown TGF-B to be inhibitory to bone growth or alkaline phosphatase 
activity in culture (Noda and Rodan 1986; Rosen et al. 1988). However, other 
studies have found that TGF-B increases alkaline phosphatase activity (Noda and 
Rodan 1987) and the synthesis of mRNAs which code for various osteoblast 
products such as procollagen and osteonectin (Noda and Rodan 1987; Penttinen, 
Kobayashi and Bornstein 1988; Strong et al. 1991), as well as DNA synthesis (Hill 
et al. 1986; Centrella, McCarthy and Canalis 1988) and collagen production and 
3[H]-thymidine incorporation (Hill et al. 1986; Hock, Centrella, and Canalis 1988; 
Centrella, McCarthy and Canalis 1987). Evidence also suggests that TGF-B 
increases the rate of synthesis of ascorbate transporter proteins or regulatory 
proteins. Dixon and Wilson (1992) found that ascorbate transport was increased 
in UMR-106 (osteoblast-like) cell cultures which had been pretreated with TGF- 
B, but that this could be blocked by cycloheximide, a protein synthesis inhibitor. 
Several studies showed a biphasic effect of TGF-B depending on its dosage
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(Centrella, McCarthy and Canalis 1988) or the age of the fetuses producing the 
TGF-6 (Hill et al. 1986).
Robey et al. (1987) showed that TGF-B might act as an autocrine factor in
fetal bovine bone-forming cells. These cells were found to express the TGF-B 
receptor and to respond to TGF-B with increased growth. TGF-B was found in 
the conditioned medium from these cells which the authors identified as
osteoblasts.
Tissue necrosis factor (TNF) is another cytokine that affects osteoclasts. Van 
der Pluijm et al. (1991) found that TNF-alpha did not alter activity of mature 
osteoclasts as measured by 45 Ca release from fetal mouse long bone, but that in 
fetal mouse bone it stimulated resorption at low concentrations and inhibited 
resorption at high concentrations.
Other growth factors
Epidermal growth factor (EGF) has been shown to affect bone resorption. 
Raisz et al. (1980) found EGF to increase release of ^Ca from cultured fetal rat 
long bone shafts. Indomethacin did not block this phenomenon. However, 
Shupnik and Tashjian (1982) found that EGF increases PGE^ production by 
osteosarcoma cells. Takahashi et al. (1986) showed that EGF can stimulate bone 
resorption by increasing the proliferation of osteoclast precursors.
Tashjian et al. (1982) showed that platelet-derived growth factor (PDGF) 
caused an increase in PGE^ production and bone resorption as evidenced by an
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increase in culture-medium calcium concentration. They suggested that PDGF 
stimulates bone resorption via enhanced PGEg production.
Spencer et al. (1991) found that when insulin-like growth factor (IGF-I) was
continuously infused into the right hindlimb arterial supply of rats, using the other 
leg as a control, IGF-I induced bone formation, stimulated osteoblastic activity, 
and decreased the number of osteoclasts. However, Slootweg et al. (1992) 
recently reported that when IGF-I was added to mouse bone cultures containing 
osteoclast precursors, the number of osteoclasts increased, as did bone resorption. 
Thus, while IGF-I seems to be primarily anabolic in its effects, it appears to 
induce bone resorption under certain circumstances.
Scheven et al. (1991) isolated what they called osteoclast growth factor 
(OGF) from fetal rat calvaria culture medium. The conditioned medium 
(containing OGF) increased the number of osteoclasts in fetal long bone cultures, 
but did not exert a direct effect on bone resorption by pre-existing osteoclasts. In 
bone marrow cultures conditioned medium stimulated formation of TRAP+
mononuclear cells. Peritoneal macrophages did not respond to conditioned 
medium. Antibody to GM-CSF did not prevent conditioned medium activity.
Prostaglandins (PG)
The prostaglandins are a ubiquitous group of compounds derived from 
arachidonic acid. Their activities are varied and complex, but they have been 
shown to play a definite role in the activation or inhibition of bone cells.
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Much research has shown that PGs mediate bone resorption. Franklin and 
Tashjian (1975) found that continuous i.v. infusion of PGf^ in rats produced 
elevated plasma calcium and phosphate levels, suggesting a breakdown of bone. 
Several studies (Rifkin et al. 1980; Schelling et al. 1980) demonstrated that PGE 
in bone cultures caused an increase in calcium release and in osteoclast number
as well as in ruffled border development. Indirect evidence, using indomethacin 
to inhibit PG synthesis, suggests that prostaglandins mediate the bone resorption 
induced by collagenase (Dowsett et al. 1976), by complement (Sandberg et al. 
1977), by EGF (Tashjian and Levine 1978), by monocytes or monocyte- 
conditioned medium (Dominguez and Mundy 1980), by PDGF (Tashjian et al. 
1982) and by IL-1 (Garrett and Mundy 1989; Linkhart and MacCharles 1992). 
Lemer (1980) found that indomethacin decreased the release of ^Ca, Ca?* , P,, 6- 
glucuronidase, S-galactosidase, and B-N-acetylglucosaminidase, as well as glucose 
consumption and lactate production in neonatal mouse calvarial organ culture. In 
addition, one study (Minkin et al. 1981) found that tumor extracts from patients 
with humoral hypercalcemia of malignancy (HHM) caused 45 Ca release in 
neonatal mouse calvaria cultures, and that this could be inhibited by 
indomethacin and eicosatetraynoic acid, indicating the involvement of 
prostaglandins. Several studies have shown that cAMP might mediate the effects 
of prostaglandins (Tashjian et al. 1982; Akatsu et al. 1989).
PGE, given subcutaneously was shown by Yonaga and Morimoto (1979) to 
inhibit longitudinal bone growth of the proximal tibia and longitudinal and
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appositional growth of the incisal dentin. They reported that the actions of PGE, 
were identical to those of CT and they felt that calcitonin might mediate the 
effects of PGE,. PG^ as well as dibutyryl cAMP were shown to produce 
identical effects to those of calcitonin in inhibiting bone resorption and osteoclast 
motility. Theophylline, which inhibits intracellular cAMP degradation, 
potentiated these effects, suggesting that CT and PG^ act by increasing cAMP 
activity.
Although most studies have shown that prostaglandins stimulate bone 
resorption, the resorption of bovine bone slices by isolated osteoclasts in culture 
was found to be inhibited by several prostaglandins in a study by Fuller and
Chambers (1989).
Several studies have provided evidence that prostaglandins can also stimulate 
bone formation. Marks and Miller (1988) showed that infusion of PGE, into 
alveolar bone in dogs over a period of five weeks caused increased bone 
formation when compared to controls. Li et al. (1990) injected dogs 
subcutaneously once a day with PGEj for 31 days and found a net increase in 
cancellous and cortical bone formation in iliac crest and mid-tibial shaft. And
Flanagan and Chambers (1992) reported that PGE, and PGEg increased bone
nodule formation in rat calvarial cell cultures.
Miscellaneous Compounds
Various other endogenous substances have been found to affect osteoclast 
morphology and activity, confirming the idea that the control of the osteoclast is
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very complex. Some of these substances and their actions will be briefly
discussed below.
Matsui et al. (1991) found that in sheep fed a protein-deficient diet the 
number of osteoclasts and the TRAP activity were lower than in control animals. 
Administration of D3 could not rectify the problem.
Plasminogen activator, produced by osteoblasts, is a factor implicated in the 
induction of bone resorption. Hamilton et al. (1984) found that PTH, PGI^, 
EGF and 1,25 (OH^Bj stimulated PA activity in osteoblasts. Hoekman et al. 
(1991) reported that bPTH(l-84), hPTH-like protein(l-34), PGI^, EL-1 beta, and 
TNF-alpha stimulated production of plasminogen activators by three different 
osteoblastic cell lines, whereas TGF-beta reduced PA production. Cheng et al. 
(1991) examined the effects of various growth factors and cytokines on secretion 
of PA and plasminogen activator inhibitor (PAI) in osteoblast-enriched calvarial 
cell cultures. Fibroblast growth factor (FGF), EGF and PDGF increased PA in 
culture medium and cell layer extract. IL-1 alpha, TNF-alpha and IGF-1 caused 
no change in PA activity. TGF-beta increased PA activity in some assays, and 
also increased PAI activity. Basic FGF and PDGF slightly increased PAI 
secretion. The authors concluded that the regulation of PA activity by growth 
factors and cytokines did not correlate with their resorbing/stimulating activities. 
Thus PA secreted by osteoblasts appears to be only one of several factors 
involved in initiation of bone resorption.
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Nitric oxide has recently been implicated in osteoclast inhibition. MacIntyre 
et al. (1991) using an isolated osteoclast culture system, found that nitric oxide 
produced a decrease in osteoclast spread area by about 50%.
Miyauchi et al. (1991) found that osteopontin binding to osteoclast 
alphaybetoj integrin causes a calmodulin-dependent reduction in cytosolic Ca++ , 
which is thought to participate in the regulation of osteoclast function.
Mundy and Poser (1983) found that osteocalcin (BGP) has chemotactic 
activity for breast cancer cells, monocytes and rat osteosarcoma cells. They 
suggested that since BGP is released during bone turnover, it might be a 
mechanism of recruiting cells for bone remodelling. Glowacki et al. (1991) 
implanted apatite, either alone or containing osteocalcin, BSA or collagen, 
subcutaneously into rats. Only the particles containing osteocalcin stimulated 
production of MNCs that were TRAP+ and that had osteoclast morphology 
(ruffled border, clear zone).
Ljunggren et al. (1991) examined the role of polyamines (putrescine, 
spermidine, spermine) in PTH-induced bone resorption. They found that PTH 
stimulated ornithine decarboxylase activity in cultured osteoblast-like cells, and 
caused a modest increase in putrescine and spermidine. However, polyamine 
synthesis inhibitors had no effect on 45 CA release, but polyamines could inhibit 
45 Ca release directly.
Malone et al. (1982) showed that type I collagen, alph^HS glycoprotein and 
osteocalcin evoke a chemotactic response in human monocytes (which they 
supposed to be osteoclast precursors).
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Oreffo et al. (1988) showed that retinol or retinoic acid increased cellular 
adhesion to substratum, acid phosphatase activity and release of 3 [HJproline as 
evidence of increased resorption in isolated chicken osteoclast cultures.
Fatemi et al. (1991) showed that magnesium deficiency in human subjects 
caused a fall in serum calcium and serum Dj. PTH either fell or did not change, 
showing an impaired PTH secretion.
Pharmacological Compounds
The bisphosphonates are a class of pharmacological compounds that have 
been shown effective in reducing bone resorption. Miller et al. (1977) found that 
a series of ethane-1-hydroxy-1,1-diphosphonate (EHDP) injections resulted in 
increases in the number of osteoclasts, osteoclast nuclei and osteoclast nuclei per 
profile, and in the rate of osteoclast production from precursors, but at the same 
time slowed bone resorption.
Carano et al. (1990) showed that several bisphosphonates reduced bone 
resorption in cultured chicken osteoclasts, and reduced IT accumulation in 
osteoclasts as measured by acridine orange staining. They also reduced osteoclast 
protein synthesis. The authors suggested that bisphosphonates reduce resorption 
by metabolic inhibition of the target osteoclasts, because the bisphosphonates 
bind to bone mineral and prevent osteoclast attachment and resorption.
Sato et al. (1991) injected 3 [H]alendronate, another bisphosphonate, into 
newborn rats. Osteoclast surfaces and bone surfaces were labelled. Osteoclasts
from adults animals infused with PTHrP and injected with alendronate lacked
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ruffled border but not clear zone. Alendronate bound to bone particles in vitro 
and inhibited bone resorption by isolated chicken or rat osteoclasts when the 
bone surface had alendronate at certain concentrations bound to it.
Bonucci et al. (1992) showed that ipriflavone has a direct inhibitory effect on 
bone resorption. They suggest that this is due to reduction in osteoclast 
recruitment or differentiation as evidenced by histomorphometric techniques.
Osteoblast Involvement in Osteoclast Activation
Many studies are pointing to an active role by osteoblasts in the recruitment 
and activation of osteoclasts. Several recent findings, in addition to studies 
already cited, are given here.
Udagawa et al. (1989) showed that when osteoblast-like cell lines were 
cultured with mouse spleen cells, osteoclast-like TRAP+ cells appeared and 
resorbed whale dentine. Yamashita et al. (1990) isolated several cell lines from 
fetal mouse calvaria and cocultured them with murine spleen cells. PTH 
increased cAMP in these osteoblast-like cells, and PTH + IL-1 also induced 
TRAP+ MNC formation in this coculture system. Contact between these (KS-4) 
cells and spleen cells was necessary for osteoclast formation to take place.
Greenfield et al. (1992) reported that conditioned medium from avian 
osteoblast cultures could stimulate bone resorption and the expression of the 
specific osteoclast antigen 121F, which they attributed to interaction of an 
osteoblast-produced factor with osteoclast precursors. Hiura et al. (1991) found 
that when spleen cell cultures were treated with conditioned medium from a
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clonal osteoblast cell line taken from "young” cells, MNC formation was inhibited 
in the presence of D3 and GM-CSF, but when the conditioned medium was taken 
from older cells, MNC formation was stimulated. PGE^ was detected in the 
conditioned medium from both "young” and "old" cells, and the inhibition induced 
by the younger cells was partially abolished by indomethacin. 60-day conditioned 
medium and Dj stimulated MNC development even in the absence of GM-CSF, 
but was inhibited by antibody to GM-CSF. The authors concluded that 
osteoblasts produce GM-CSF which stimulates MNC formation, and PGEg which 
inhibits MNC formation, and they suggested that different stages of osteoblast 
development determine the effects of the conditioned medium on osteoclast 
development.
Fuller et al. (1991) proposed that osteoblasts mediate osteoclast activation by 
releasing "osteoclast resorption-stimulating activity" (ORSA), and that this product 
is bound either to glycosaminoglycans (GAG) of bone matrix or to the osteoblast 
cell surface. They suggested that this immobilization of ORSA by GAG might 
aid the osteoblasts in regulation of osteoclast activity.
The Calcium Deficiency Model
The calcium deficiency model has been an effective tool in studying bone cell 
dynamics in vivo. Giving rats a calcium-deficient diet or replenishing calcium 
stores lost due to deficiency causes a shift in the bone resorption/bone formation 
equilibrium as the populations and activities of osteoclasts and osteoblasts are
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modulated. This model also gives insight into the control of bone metabolism by 
local and systemic humoral factors.
Some early studies (Stauffer et al. 1972; Stauffer et al. 1973) showed that 
feeding rats a calcium-free diet for up to twelve days resulted in an increase in 
the medullary area of the tibia in cross-section. This was accompanied by 
hypocalcemia, inhibition of bone formation, increased bone resorption and an 
increase of parathyroid gland volume. These findings agreed with those of de 
Winter and Steendijk (1975) who reported a decrease in cortical bone area in the 
mid-shaft of the femur during calcium-deficiency in lactating rats, with bone 
losses in the endosteum and in the spongiosa. It was also reported that 
mineralization during this deficiency period was delayed, and the rate of mineral 
deposition was decreased (Stauffer et al. 1973). Weinreb, Rodan and Thompson 
(1991) showed an elevation in serum PTH with calcium deficiency, although 
serum calcium was not affected. They also reported a reduction in femoral ash 
weight, in tibial cortical thickness and in trabecular bone volume in calcium- 
deficient animals.
Giving calcium-deficient animals a normal calcium-containing diet caused a 
decrease in medullary area as bone formation replaced bone resorption, but it 
took months to replace the amount of bone that was lost in a 1- to 2-week
calcium deficiency period (Stauffer et al. 1972; Drivdahl, Liu and Baylink 1984). 
Stauffer et al. (1972) also reported that the increased bone formation during
calcium repletion took place primarily in areas where resorption had taken place
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during calcium deficiency. De Winter and Steendijk (1975) also found that, while 
calcium repletion increased the amount of bone formation, the cortical bone area 
did not return to normal after 3 weeks calcium repletion. They discovered that 
bone density in the newly-formed bone was lower than in normal animals.
The increase in resorption during calcium deficiency can be attributed to an 
increase in osteoclast numbers, size, and number of nuclei (Thompson, Baylink 
and Wergedal 1975). However, the number of osteoblasts has also been reported 
to increase in proportion to the number of osteoclast nuclei, thus indicating a 
coupling mechanism between resorption and formation. Liu, Baylink and 
Wergedal (1975) found that neither calcitonin, PTH, nor mechanical stress was 
necessary to bring about repletion in calcium-deficient rats, but that the rate of 
bone formation during repletion was related to the seriousness of the calcium 
depletion during the deficiency period.
Hughes et al. (1975) demonstrated that low calcium or low phosphorus diets 
increased the concentration of circulating l,25(OH)^Dtj, but while the effect of 
calcium deficiency on the Dtj response was dependent on intact parathyroid 
glands, the response due to phosphorus deficiency was independent of these
glands.
Liu, Baylink and Wergedal (1978) revealed that calcium repletion is not 
dependent on mechanical stress. They rendered one hind limb immobile in a 
group of rats by transecting the sciatic nerve, and found that there was no 
difference in the rate of repletion between immobilized animals and normal
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animals. However, Weinreb, Rodan and Thompson (1991) found that 
immobilization of a limb due to nerve transection did cause additional loss of
bone mass, and an increase in osteoclast numbers beyond what could be 
accounted for by calcium deficiency alone.
Liu, Ivey and Baylink (1981) examined the effects of vitamin D deficiency on 
calcium repletion. They found that although D deficiency caused serious 
hypocalcemia and elevated serum PTH, these factors did not prevent repletion.
In fact, there was a depression in the resorption rate of repleting animals showing 
that PTH-mediated bone resorption was being suppressed. Vitamin D-deficient 
animals did show some impairment in mineralization.
McMillan et al. (1989) demonstrated that giving a calcium-containing diet to 
deficient rats caused rapid changes in osteoclast morphology suggesting increased 
osteoclast inhibition. They found that within three hours of the beginning of a 
calcium-containing meal, decreases in the ruffled border index and the osteoclast 
contact index could be measured. This was accompanied by increases in the 
osteoclast isolation index, showing that other cells were already beginning to 
insert themselves between the osteoclasts and the bone surface. (For definitions 
of these indices, see p. 38)
Sissons, Kelman and Marotti (1985) made use of the calcium deficiency 
model to show that there was no increase in the size of osteocyte lacunae with 
calcium deficiency, suggesting that osteocytic osteolysis did not take place.
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Effects of Fasting
Many of the studies concerning fasting have dealt with weight loss in obese 
people, or have focused on changes in carbohydrate, lipid and protein metabolism 
(eg., Young and Scrimshaw 1971). While experiments examined such topics as 
the effects of fasting on liver and kidney metabolism (Owen et al. 1969), pancreas 
(Webster et al. 1972), and magnesium depletion (Drenick, Hunt and Swendseid 
1969), little is known about the effects of fasting on bone cell activity.
One study dealing with calcium homeostasis (Wong and Klein 1984) showed 
that there is a circadian shift between bone and diet (i.e., intestine) as sources of 
blood calcium in dogs, with bone normally accounting for two thirds of the blood 
calcium and diet providing one third. Dogs were given multiple injections of ^Ca 
over a period of six weeks, with experiments starting four weeks after the end of 
labeling. In dogs on normal calcium-containing diets, the concentration of 45 Ca in 
serum fluctuated following a circadian pattern, but the total serum calcium level 
remained constant. The authors found that when dogs were put on a low calcium 
diet or fasted, the labelling of blood calcium was high, and the level of serum 
45 Ca no longer fluctuated, indicating that bone was providing essentially all of the 
blood calcium. In thyroparathyroidectomized dogs, however, the labelling of 
blood calcium was low and did not fluctuate, showing that calcium derived from 
intestinal absorption had become the primary source of serum calcium.
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Focus of This Study
Data reported by Liu et al. (1982) showed that virtually all osteoclasts that 
had been recruited to tibial endosteum by 12 days of dietary calcium deficiency 
disappeared following 24-72 hours of dietary calcium supplementation. Together 
with the finding by McMillan et al. (1989) that a change in osteoclast morphology 
suggesting a reduction in osteoclast activation is apparent after as little as three 
hours following calcium supplementation, it was concluded that at some time 
point between 3 hours and 24 hours, osteoclasts were being "shut down" and were 
withdrawing from the endosteum. Consequently, the hypothesis was formulated 
that there exists some temporal and/or quantitative dietary calcium threshold 
beyond which osteoclasts will be completely inhibited and will recede from bone, 
and that once osteoclasts have reached this point, a certain minimum time will be 
required for osteoclast re-recruitment to bone.
A secondary hypothesis was generated as a result of the first experiment in 
this study. The data from this experiment suggested that fasting had reversed the 
morphological changes brought about by calcium supplementation; therefore, the 
hypothesis was proposed that fasting can reactivate inhibited osteoclasts. It was 
further proposed that fasting might be effective in initially recruiting osteoclasts.
The goal of this study, then, was to examine the modulations of osteoclast 
morphology following changes in dietary calcium supplementation in calcium- 
deficient rats. This study has been divided into two parts; the first part examines 
the dietary control of osteoclast recession (withdrawal from bone), and the second
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part focuses on how dietary factors (fasting and calcium deficiency) influence the 
osteoclast recruitment or activation processes.
MATERIALS AND METHODS
In all experiments, male Sprague-Dawley rats, aged 21-28 days, beginning 
weight approximately 50 g, were used. Animals were housed either individually 
or in groups. The animals were put on a 12/12 light/dark cycle; in some of the 
studies a reversed light cycle was used to facilitate the execution of the feeding 
protocol. Animals that were put on a reversed lighting cycle (lights on nights, 
lights off days) were fed standard lab chow during a six-day period of habituation 
to the new lighting cycle. Otherwise all animals were fed either a custom normal 
calcium diet containing 0.7% phosphorus and 0.7% calcium, or a custom calcium 
free diet with 0.4% phosphorus and 0.0% calcium (ICN Biochemicals, Cleveland) 
(see Appendix A for diet composition), and tap water ad libitum. At the 
completion of each experiment, the animals were deeply anesthetized either by 
inhaling ether or by i.p. injection with 50% urethane, then killed by perfusion
with a glutaraldehyde fixative (1.75% glutaraldehyde, 0.08 M sucrose, 0.05 M
cacodylate buffer, pH 73). Tibia were removed, stripped of soft tissues, and
decalcified in a solution of 3.7% EDTA, 5% glutaraldehyde, 0.033 M cacodylate
buffer, pH 73, and 6.85% sucrose for one to two weeks. The tibias were then cut 
into 2 mm segments and washed three times at 15 minutes each in 0.1 M 
cacodylate buffer, pH 73, followed by 2 hours in 1% Os04 in cacodylate buffer. 
The bone fragments were next dehydrated in a graded acetone series, changed to 
propylene oxide (2 treatments at 15 min. each), and put in 1:1 propylene 
oxide :epon (Polybed 812) for 3 hours. The tissues were changed to a 1:2 
propylene oxide:epon mixture and left overnight, then embedded in epon. One
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nm tibial cross-sections were cut using a Porter Blum Ultramicrotome MT-2. 
The sections were stained for 5 minutes with a warm solution of 5 parts 1% 
toluidine blue/1% azure II in 4 parts 5% N^CQj, rinsed three times in HgO, 
then mounted on slides and heat-dried. Cover slips were mounted with
Permount.
Morphometric Analysis
A total of three tissue sections, one section from each of three blocks, were 
examined per animal using the DATAVOICE computerized voice command data 
collection system. All slides were examined at 1000 x with a Zeiss light 
microscope equipped with a camera lucida, and using a digitizing pad to register 
x,y coordinates. This program made it possible to simultaneously measure the 
total length of the endosteal surface in these tibial cross-sections, and determine 
the various bone morphological indices which are described below. These indices 
are based on the stereological principle that the length of the boundary of a 
feature in a two-dimensional tissue section is proportional to the surface area of 
that feature in three dimensions.
Morphological Indices:
Osteoblast Area Fraction (OBAF): The percentage of the total length of 
endosteal surface covered by osteoblasts.
Resting Area Fraction (RAF): The percentage of the total length of 
endosteal surface covered by resting/bone lining cells.
Osteoclast Area Fraction (OCAF): The percentage of the total length of 
endosteal surface covered by osteoclasts. The OCAF can be subdivided 
into the following categories:
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Ruffled Border Index (RBI): The percentage of the 
osteoclast/bone interface demonstrating ruffled 
border.
Contact Index (Cl): The percentage of the osteoclast/bone 
interface demonstrating physical bone/cell contact (including 
ruffled border).
Separation Index (SI): The percentage of the osteoclast/bone 
interface demonstrating a gap (as determined visually) 
between part of the cell and bone.
Isolation Index (II): The percentage of the osteoclast/bone 
interface where the osteoclast is partially isolated from the 
bone by another cell type.
Removed Index (REM): The percentage of the total endosteum
demonstrating osteoclasts completely removed from the bone surface and 
separated from the bone by other cell types. (This index is calculated 
separately from all other measurements.)
Statistical Analysis
The various treatment groups in each experiment were compared by ANOVA 
using the CRISP statistical package (Crunch Software Corporation, San 
Francisco). The p values for the ANOVA are based on the Fmax ratio, and post- 
hoc t-tests were used for comparisons between groups within each experiment.
RESULTS
Dietary Control of Osteoclast Recession
The first three experiments in this study examined the induction of osteoclast 
recession from bone by calcium supplementation, and examined the effects of 
fasting on this osteoclast recession.
Experiment #1: Inhibition of Osteoclasts by Dietary Calcium in Calcium-
Deficient Rats is Graded
It was shown by Liu et al. (1982) in calcium-deficient rats, that receiving 
calcium-containing diet for 1 to 3 days caused virtually all osteoclasts to disappear 
from the endosteal surface of the tibial diaphysis. McMillan et al. (1989) showed 
that this inhibition first becomes morphologically apparent after as little as three 
hours of calcium supplementation. Apparently, at some point between 3 hours 
and 24 hours, osteoclasts were being totally inhibited. Two alternatives were 
considered: first, that osteoclast inhibition might require a certain dietary calcium 
threshold, and that when this threshold was reached, one would observe a rapid 
decline in the number and activity of osteoclasts until all osteoclasts had virtually 
disappeared. The second option was that osteoclast inhibition was graded, that is, 
that with increasing dietary calcium supplementation, morphological indices would 
gradually change in a dose- and/or time-dependent manner, demonstrating 
increased osteoclast inhibition, until the osteoclasts had completely withdrawn 
from bone. The goal of the first experiment was to test the hypothesis that 




Seven groups of 6 rats were used. Animals were kept in a darkened room 
and subjected to a reversed light cycle (lights on 21:00, light off 9:00). The 
animals were given six days to adjust to the reversed lighting before beginning the 
experiment. During this time the rats were given lab chow ad libitum. After this 
habituation period, animals were fed either the custom normal calcium diet or 
the custom calcium free diet ad libitum during the dark period of the light/dark 
cycle. On day eight, the animals were given 6 grams of diet divided into five 
1.2 g feedings three hours apart. Each group followed an individual feeding 
protocol:
Normal controls: received only normal calcium diet for eight days
Deficient controls: received only calcium free diet for eight days
3-hour supplemented: received calcium free diet seven days, normal calcium 
diet on day 8 for first feeding only, with calcium free diet for remaining 
feedings
6-hour supplemented: received calcium free diet seven days, normal calcium 
diet on day 8 for first two feedings only, with calcium free diet for 
remaining feedings
9-hour supplemented: received calcium free diet seven days, normal calcium 
diet on day 8 for first three feedings only, with calcium free diet for 
remaining feedings
12-hour supplemented: received calcium free diet seven days, normal calcium 
diet on day 8 for first four feedings only, with calcium free diet for the 
remaining feeding
Total supplemented: received calcium free diet seven days, normal calcium 
diet on day 8, all feedings
The animals were killed at 9:00 on the day following the last feeding (day 9) and 
tissues prepared as described above for morphological analysis.
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In this and all subsequent experiments, there were no significant differences 
in amount of food consumed or weight gained between experimental groups. 
Table 1 (page 43) shows the means _+ SEM for the 8 parameters measured. A 
comparison of the normal and the deficient control groups using the t-test showed 
significant differences between the two groups in 4 of the 8 morphological 
indices: OBAF (normal > deficient; p = 0.003), OCAF (deficient > normal; p=0.002) 
(see Figure 1, page 44), Cl (normal [mean = 93.1; SD = 3.5] > deficient
[mean = 87.9; SD = 3.8]; p = 0.048), and II (deficient>normal; p = 0.032) (see
Figure 2, page 45). When the deficient control group was compared with the 
experimental groups using ANOVA, no significant differences could be found 
between groups, although there was evidence of a trend toward the reduction of 
the ruffled border index with increasing amounts of normal calcium diet (see
Figure 3, page 46).
In this experiment, it had been expected that increasing amounts of calcium 
supplementation would produce changes in osteoclast morphology indicating an 
increased tendency toward recession from bone. This increased recession would 
be manifested by a decrease in the ruffled border index, and by a decrease in the 
percentage of the osteoclast/bone interface characterized by actual contact of the 
osteoclast with the bone surface (Cl), as well as by a decrease in the percentage 
of the endosteal surface covered with osteoclasts (OCAF). This should have been 
accompanied by an increase in the II and in the SI. It was also hypothesized that 
there would be an increase in the percentage of osteoclast profiles completely 
removed from the bone (REM).
SICl II REMOCAF RBIGROUP OBAF RAF
2.0 + 3.2 4.9 + 2.3 0.1 + 0.293.1 + 3.553.2 + 5.1 10.2 + 4.8 15.4 + 5.5N.C. 36.6 + 5.7
7.9 + 1.0 0.6 + 0.587.9 + 3.8 4.2 + 3.332.2 + 9.5 19.2 + 4.148.8 + 6.319.0 + 8.0D.C.
0.1 + 0.24.5 + 2.0 7.4 + 2.988.1 + 3.321.8 + 6.9 22.4 + 6.753.1 + 9.325.1 + 11.73 Hr
0.3 + 0.53.2 + 2.7 6.9 + 2.389.9 + 4.930.4 + 9.2 19.0 + 5.242.5 + 9.327.2 + 12.96 Hr
6.4 + 1.6 0.6 + 0.786.7 + 6.1 6.9 + 4.925.1 + 7.1 11.9 + 6.052.7 + 4.19 Hr 22.3 + 5.9
0.3 + 0.44.6 + 2.23.2 + 1.616.3 + 6.1 92.2 + 1.456.6 + 12.5 21.3 + 4.712 Hr 22.1 + 11.6
0.1 + 0.17.7 + 4.82.3 + 1.111.5 + 6.2 89.9 + 5.751.8 + 10.7 25.1 + 3.523.1 + 11.5TOT
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FIGURE 1: Osteoblast Area Fractions (white bars), Resting Area Fractions 
(diagonally striped bars), and Osteoclast Area Fractions (crosshatched bars), 
means _+ SEM. Experimental groups: N.C. = normal control, D.C. = deficient 
control, 3 Hr = 3-hour supplemented, etc., TOT. = total supplemented (see 
text), n = 5 for the 3-hour supplemented group; n = 6 for all other groups.
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EXPERIMENT #1
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FIGURE 2: Separated Index (white bars) and Isolation Index (striped bars), 
means ± SEM. Experimental groups: N.C. = normal control, D.C. = deficient 
control, 3 Hr = 3-hour supplemented, etc., TOT. = total supplemented (see 
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FIGURE 3: Ruffled Border Index, means ± SEM. Experimental groups: N.C. = 
normal control, D.C. = deficient control, 3 Hr = 3-hour supplemented, etc., 
TOT. = total supplemented (see text), n = 5 for the 3-hour supplemented 
group; n = 6 for all other groups.
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Of the eight morphological indices measured, none showed a significant 
change with increasing calcium supplementation. However, the trend toward a 
reduction of ruffled border with increasing calcium supplementation suggested 
that there was an increasing inhibition of osteoclast activity with increasing 
administration time of calcium.
The feeding protocol which was followed on the eighth day of the experiment 
called for a twelve-hour fasting period at the end of the calcium feeding period, 
before killing the animals, in order to use a total 24-hour time frame so that the 
results of this experiment could be compared with those of liu et al. (1982). In 
analyzing the data, the conclusion was reached that it was because of this fasting 
period that the morphological indices did not show significant differences between 
groups. It was hypothesized that the fast lowered the blood calcium levels 
sufficiently to stimulate osteoclast reactivation, resulting in a lack of statistical 
differences between groups in osteoclast morphology indicating osteoclast 
inhibition.
A discrepancy should be noted between the results of this experiment and the 
subsequent experiments. In this first experiment, it was found that the contact 
index was greater in the normal than in the deficient controls, while the deficient 
controls showed a greater isolation index than the normal controls. No significant 
differences in these parameters between normal and deficient controls were found 
in subsequent experiments. A higher contact index suggests a greater degree of 
osteoclast activity, while a higher isolation index implies greater osteoclast
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inhibition or greater osteoclast mobility. The results of experiment #1 could be 
an indication that the osteoclasts that were present in the normal controls were 
less mobile than those in the deficient group. Mobility could serve as an 
indicator for the degree of activation of the osteoclast. However, since results 
from subsequent experiments do not confirm these results, the significance of the 
data of this first experiment must be called into question.
It is interesting to note that the notion of resorption-formation coupling is not 
well supported by the present data. Based on the coupling theory, one would 
expect that when bone resorption increases, bone formation would have to 
increase in order to maintain an equilibrium between the two phenomena. In the 
calcium-deficient animal, there is a significant increase in the osteoclast area 
fraction, which is an indicator of increased resorption. However, there is a 
decrease in the osteoblast area fraction, suggesting a reduction in bone formation. 
The resting area fraction is comparable for the two groups. One would think that 
the osteoblast area fraction would have increased with the osteoclast area fraction
in the deficient animals, with a decrease in the resting fraction, but this is not 
seen. This could be explained, perhaps, either by the severity of the deficiency 
making it impossible for bone formation to keep pace with resorption, or by a lag 
time in the formation process.
Experiment #2: Fasting Can Reverse Osteoclast Recession
The results of the first experiment led to the hypothesis that a 12-hour fast is 
sufficient to reverse the morphological changes toward recession manifested by
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osteoclasts after twelve hours of calcium supplementation. It was therefore 
necessary to design an experiment which would compare two calcium- 
supplemented groups, one which would fast for 12 hours following the calcium 
supplementation, and the other which would be killed immediately at the end of 
the calcium supplementation period
Four groups of six animals were used, with reversed lighting (lights on 20:30, 
lights off 8:30), and a habituation period of 6 days. The normal and deficient 
control groups received only normal calcium diet or calcium free diet during the 
entire experiment. The non-fasting experimental group received calcium free diet 
7 days, and on day 8 received 6 grams of normal calcium diet spread over four 
feedings. These first three groups were killed immediately after the last feeding 
period. The last group, the fasted experimental group, was fed the calcium free 
diet for 7 days, and on day 8 received 6 grams of normal calcium diet spread over 
four feedings, but these animals fasted 12 hours before being killed.
Table 2 (page 50) summarizes the results of experiment #2. The two control 
groups, when compared by t-test, differed significantly in OBAF (normal > 
deficient; p < 0.05) and OCAF (deficient > normal; p < 0.001) (see Figure 4, 
page 51). The supplemented non-fasting group differed significantly from the
deficient controls in RAF, OCAF, RBI (Figure 5, page 52), Cl (Figure 6, page 
53), SI (Figure 7, page 54), and II (Figure 8, page 55). Of these six indices, only
RAF remained significantly elevated in the fasting group when compared to the 
deficient control group.
SI IIGROUP RAF OCAF RBI ClOBAF
82.4 + 11.7 4.9 + 6.8 12.8 + 6.854.2 + 12.3 6.9 + 3.5 17.1 + 14.939.4 + 13.0N.C.
4.0 + 3.3 11.5 + 1.848.5 + 6.5 28.4 + 10.6 23.4 + 7.6 84.5 + 4.124.1 + 10.1D.C.
4.7 + 2.5 11.0 + 3.421.0 + 5.6 18.8 + 5.3 84.3 + 4.118.0 + 9.8 62.1 + 10.0FAST
14.3 + 4.4 22.1 + 4.815.0 + 3.9 63.6 + 5.925.3 + 5.0 61.8 + 6.4 8.5 + 2.4NO FAST
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FIGURE 4: Osteoblast Area Fraction (white bars), Resting Area Fraction 
(striped bars), and Osteoclast Area Fraction (crosshatched bars), means +_ 
SEM. Experimental groups: N.C. = normal control, D.C. = deficient control, 
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FIGURE 5: Ruffled Border Index, means ± SEM. Experimental groups: N.C. = 
normal control, D.C. = deficient control, FAST = fasted supplemented, NO 
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FIGURE 6: Osteoclast Contact Index, means _+ SEM. Experimental groups: 
N.C. = normal control, D.C. = deficient control, FAST = fasted 
supplemented, NO FAST = non-fasted supplemented, n = 6 for all groups.
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EXPERIMENT #2
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FIGURE 7: Osteoclast Separation Index, means ± SEM. Experimental groups: 
N.C. = normal control, D.C. = deficient control, FAST = fasted 
supplemented, NO FAST = non-fasted supplemented, n = 6 for all groups.
55
EXPERIMENT #2













FIGURE 8: Osteoclast Isolation Index, means ± SEM. Experimental groups: 
N.C. = normal control, D.C. = deficient control, FAST = fasted 
supplemented, NO FAST = non-fasted supplemented, n = 6 for all groups.
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The results indicate that the 12 hours of calcium supplementation is sufficient 
to cause morphological changes in osteoclasts that are indicative of inhibition.
The supplemented group had a decreased OCAF and an increased RAF 
compared to the deficient control, suggesting that a decrease in osteoclast activity 
due to calcium-induced inhibition is balanced by an increase in the resting cell 
fraction, an indication that while osteoclasts are rapidly shut down, osteoblastic 
activity is not immediately increased.
The indices of osteoclast activity, namely the ruffled border index and the 
contact index, are both decreased in the non-fasting supplemented group 
compared to the deficient control animals, while indices of osteoclast inhibition, 
the osteoclast separation and isolation indices, have both increased in the non­
fasting supplemented animals as compared to the deficient controls. Both of 
these facts support the idea that 12 hours of calcium supplementation in calcium- 
deficient animals is sufficient to initiate osteoclast recession. In this and in all
subsequent studies, the removed index failed to show significant differences 
between groups, and so will not be discussed further. This apparent lack of 
statistical differences was attributed to the difficulty in identifying osteoclasts or 
osteoclast fragments morphologically, without the use of specific cytoplasmic 
markers, once the osteoclasts have left the bone surface.
Whereas the non-fasting supplemented group shows very significant 
morphological differences from the deficient controls, the fasting group is difficult 
to distinguish from the deficient animals. Only the RAF remains significantly
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higher in the fasting supplemented animals than in the deficient animals 
(p < 0.01), suggesting that the resting population might act as a sort of buffer 
when rapid changes take place at the endosteum. The other morphological 
indices have all returned to deficient control values, indicating that the fast is 
effective in reactivating osteoclasts that have been at least partially inhibited by 
calcium supplementation.
Experiment #3: Graded Response of Osteoclasts Demonstrated by
Comparing Restricted to ad libitum Calcium 
Supplementation
In experiment #2, weanling rats were given a calcium-deficient diet for 7 days 
followed by a calcium-containing diet for 12 hours, and then immediately killed. 
The feeding protocol on day 8 consisted of 4 feedings of 1.5 grams each, at 3- 
hour intervals, for a total of 6 grams over twelve hours. This feeding schedule 
was used because it was felt that in order to be sure all animals ate the same
amount of food, and attained similar serum calcium levels, both the amount of 
food and time frame of the feedings needed to be controlled. The reason for 
giving 6 grams of diet was that in a previous experiment it was found that the rats 
consumed an average of 7 grams of diet per 12-hour feeding period. It was 
thought that if given slightly less than the 7-gram average, the animals would be 
likely to consume aU food presented to them.
In preparation for experiment #2, the diet for the special feeding to be 
carried out on day 8 was weighed out into 1.5 gram aliquots and sealed in plastic 
pouches before the experiment began, so that the feeding could be carried out
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with the greatest possible ease and efficiency. In monitoring the consumption of 
food during the 7-day deficiency period, when animals were allowed to eat to 
satiation during each daily 12-hour feeding period, it was found that these animals 
were consuming an average of 10 to 13 grams per 12-hour period, as opposed to 
the 7 grams that had previously been observed. This led to the question of 
whether the restricted supplementation would put the experimental animals in a 
semi-fasting state. A hypothesis was proposed stating that the restricted calcium 
supplementation regime given on day eight would cause a smaller change in 
osteoclast morphology than an ad libitum supplementation. In this third 
experiment, comparison was made between the restricted feeding schedule used 
in experiment #2 and ad libitum feeding. The hypothesis that 24 hours of ad 
libitum calcium supplementation would bring about greater morphological 
changes in osteoclasts and other endosteal cells than 12 hours of calcium 
supplementation was also tested.
Three groups of 6 rats were used, again with reversed lighting and a six-day 
habituation period. All three groups received calcium free diet for 7 days. On 
day 8, the first group received four feedings of 1.5 g of normal calcium diet per 
feeding, at three-hour intervals, over a 12-hour period as in experiment #2.
Group 2 received normal calcium diet ad libitum for 12 hours. Group 3 received 
24 hours normal calcium diet ad libitum. Each group was killed at the end of the 
supplemented feeding period.
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See table 3 (page 60) for a summary of the results of experiment #3. 
Significant differences were found between the restricted and 12-hour ad libitum 
groups in RAF (ad libitum > restricted; p=0.01)(Figure 9, page 61), OCAF 
(restricted > ad libitum; p=0.001)(Figure 9, page 61), RBI (restricted > ad 
libitum; p=0.002)(Figure 10, page 62), Cl (restricted > ad libitum; 
p=0.03)(Figure 11, page 63) and II (ad libitum > restricted; p=0.03)(Figure 12, 
page 64). Some differences were also found between the 12-hour and 24-hour ad 
libitum feeding groups: OBAF (24-hour > 12-hour; p=0.03)(Figure 9, page 61) 
and OCAF (12-hour > 24-hour; p=0.03)(Figure 9, page 61). The OCAF was 
also significantly greater in the restricted group than in the 24-hour ad libitum 
group (p<0.0001)(Figure 9, page 61).
The 12-hour ad libitum group was more effective in bringing about osteoclast 
recession than the restricted supplemented group, since the OCAF was 
significantly lower in the ad libitum group. Again, the resting cell fraction seemed 
to compensate for the decrease in osteoclast numbers, while the osteoblast 
fraction did not change. A decrease in the ruffled border and the contact indices, 
and an increase in the separation and isolation indices, also demonstrated the 
effectiveness of the ad libitum feeding protocol in inducing osteoclast recession 
compared to the restricted regime.
Interestingly, after 24 hours of ad libitum feeding, the osteoblast area fraction 
began to increase, suggesting an increase in osteoblastic activity, as the osteoclast 
area fraction continued to decrease. This suggests two things: first, that osteoclast
Cl SIOCAF RBI IIGROUP OBAF RAF
18.1 + 6.33.0 + 1.778.9 + 5.619.8 + 4.6 13.7 + 4.956.7 + 4.924.1 + 5.9Res.
4.4 + 2.3 28.4 + 4.667.2 + 5.311.8 + 3.2 3.3 + 1.712 ad 21.2 + 11.4 67.5 + 8.9
26.0 + 9.72.9 + 3.18.5 + 6.0 71.1 + 12.37.3 + 1.624 ad 60.6 + 4.032.4 + 4.9
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FIGURE 9: Osteoblast Area Fraction (white bars), Resting Area Fraction 
(striped bars), and Osteoclast Area Fraction (crosshatched bars), means ± 
SEM. Experimental groups: Restricted = restricted supplemented, 12 ad lib - 
12-hour ad lib supplemented, 24 ad lib = 24-hour ad lib supplemented, 
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FIGURE 10: Ruffled Border Index, means _+ SEM. Experimental groups: 
Restricted = restricted supplemented, 12 ad lib = 12-hour ad lib 
supplemented, 24 ad lib = 24-hour ad lib supplemented, 
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FIGURE 11: Osteoclast Contact Index, means ± SEM. Experimental groups: 
Restricted = restricted supplemented, 12 ad lib = 12-hour ad lib 
supplemented, 24 ad lib = 24-hour ad lib supplemented, 
n = 6 for all groups.
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EXPERIMENT #3
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FIGURE 12: Osteoclast Isolation Index, means _+ SEM. Experimental groups: 
Restricted = restricted supplemented, 12 ad lib = 12-hour ad lib 
supplemented, 24 ad lib = 24-hour ad lib supplemented, 
n = 6 for all groups.
65
inhibition is more rapid than osteoblast stimulation; and second, that the rats 
must have continued eating a significant amount of food even during the light 
part of the light/dark cycle in order for the OCAF to have continued to decrease, 
since a fast would have tended to increase the OCAF.
As a result of this experiment, it was decided to feed the animals ad libitum
and to leave the food in the cage during both the light and dark periods of each
daily cycle in subsequent experiments.
Summary of Part 1
McMillan's work had shown that changes in osteoclast morphology indicating 
a movement toward recession could be detected after 3 hours on a calcium-
containing diet. It was thought that increasing the amount of calcium 
supplementation would increase osteoclast recession until a point of total removal 
from bone had been achieved. However, the results did not bear this out. The
group receiving the most calcium supplementation showed a trend toward 
decreased RBI but this was not statistically significant These results were
attributed to the 12-hour fast.
The next experiment showed that the fast did in fact reverse the changes in 
osteoclast morphology brought about the calcium supplementation. And the third 
experiment showed that ad libitum feeding of the normal calcium diet was more 
effective in bringing about osteoclast recession than the restricted regime that 
had been used in previous experiments. This evidence supported the hypothesis
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that osteoclast inhibition is a graded phenomenon, responding, in part, to the 
amount of calcium given after the period of calcium deficiency.
These three experiments indicated that short-term fasting could reactivate 
inhibited osteoclasts. The question arose whether longer-term fasting could be a 
means of initially recruiting osteoclasts in normal animals. The second part of 
this study compared the effects of fasting and calcium deficiency on osteoclast 
recruitment and on changes in endosteal cell populations.
Osteoclast Recruitment by Fasting and Calcinm Deficiency
Experiment #4: Fasting vs Calcium deficiency as a Means of Osteoclast 
Activation
Having shown that fasting could reactivate osteoclasts that had begun 
receding from the bone surface, it was necessary to examine and compare fasting 
and calcium-deficient diet as ways of initially recruiting and activating osteoclasts, 
in order to see if the same principles were operating in both situations, or 
whether the mechanisms were different
Four groups of six rats were given calcium-containing diet for 7 days. Two 
groups were then fasted either 24 or 48 hours, and two groups received calcium 
free diet ad libitum for either 24 or 48 hours. All animals were killed
immediately after the fasting or feeding period and tissues were prepared for 
morphometric analysis.
Table 4 (page 67) shows the results for experiment #4. The 48-hour fasting 
group had a smaller OBAF than the other three groups (p<0.05), and a greater 
RAF than the other groups (p<0.001)(Figure 13, page 68). The 48-hour calcium
Cl SI IIOCAF RBIOBAFGROUP RAF
0.4 + 0.4 6.1 + 2.893.5 + 2.829.4 + 9.445.8 + 16.8 10.8 + 5.043.5 + 19.224 FAST
6.3 + 4.11.1 + 1.425.1 + 17.0 92.6 + 5.48.6 + 4.673.7 + 9.148 FAST 17.7 + 8.6
5.0 + 3.51.5 + 3.220.1 + 10.1 93.6 + 5.410.1 + 6.539.1 + 13.824 DEF. 51.0 + 18.9
2.4 + 4.8 6.5 + 4.791.2 + 8.916.7 + 11.617.3 + 7.638.9 + 9.0 44.2 + 8.548 DEF.
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FIGURE 13: Osteoblast Area Fraction (white bars), Resting Area Fraction 
(striped bars), and Osteoclast Area Fraction (crosshatched bars), means +. 
SEM. Experimental groups: 24 H F = 24-hour fasted, 48 H F = 48-hour 
fasted, 24 H D = 24-hour deficient, 48 H D = 48-hour deficient, n = 6 for 
all groups.
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free group had a greater OCAF than the other groups, but the difference was 
only statistically significant between the 48-hour calcium free group and the 48- 
hour fasting group (p=0.02)(Figure 13, page 68). The other morphological 
indices showed no significant differences between groups. These results suggest 
that fasting shuts down osteoblast activity, but instead of stimulating osteoclast 
recruitment and activation, the resting cell fraction increases. Fasting, then, 
would seem to maintain serum calcium levels by stopping bone formation (but 
not by increasing resorption), as indicated by the decreased OBAF and the 
increased RAF in the 48-hour fasting group. On the other hand, the results of 
48-hour of calcium deficiency, that is, an increase in the OCAF, suggest that in a 
calcium-deficient state, calcium homeostasis is maintained, at least short-term, by 
an increase in bone resorption.
Experiment #5: De novo Osteoclast Recruitment vs Re-recruitment by Calcium 
Deficiency
The previous experiments in this study have indicated that short-term 
fluctuations in dietary calcium have the effect of modulating osteoclast activity 
rather than bringing in new osteoclasts or removing old ones. Osteoclasts appear 
to be under dynamic control rather than a simple OFF/ON mechanism. While 
osteoclasts begin to show morphological changes rapidly with calcium 
supplementation, it appears that approximately 24 or more hours of calcium 
supplementation is required to cause recession of the entire osteoclast population 
from bone. The final hypothesis to be tested was that osteoclasts that had been 
inhibited could be re-recruited, which would be evidenced by a more rapid rate of
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recruitment than an initial osteoclast recruitment. The outcome of this
experiment would depend on the fate of the inhibited osteoclast.
Six groups of 6 animals were used, as defined below:
7-day deficient control: 7 days calcium free diet 
9-day normal control: 9 days normal calcium diet 
9-day deficient control: 9 days calcium free diet
Supplemented control: 7 days calcium free diet followed by 2 days normal 
calcium diet
De novo recruitment: 9 days normal calcium diet, 2 days calcium free diet
Re-recruitment: 7 days calcium free diet, 2 days normal calcium diet, 2 
days calcium free diet
Animals were killed immediately after the last feeding and tissues prepared for 
morphometric analysis.
The results of experiment 5 are summarized in table 5 (page 71). Results of 
analysis of variance showed that the re-recruitment group had a significantly 
greater OBAF (p<0.01), and a smaller RAF (p<0.01) than all the other groups 
(Figure 14, page 72). The two calcium deficient controls had significantly greater 
OCAFs than the other four groups (p< 0.005), and the de novo recruitment group 
had a greater OCAF than the normal (p = 0.05) and supplemented controls 
(p<0.05) and the re-recruitment group (Figure 14, page 72). The supplemented 
control had a significantly smaller RBI (p < 0.01)(Figure 15, page 73) and Cl 
(p < 0.0001)(Figure 16, page 74) and a greater SI (p < 0.05)(Figure 17, page 75) 
and II (p < 0.0001)(Figure 18, page 76) than all the other groups. Another 
parameter, the average osteoclast profile width, was measured in this study.
GROUP OBAF Cl SIRAF OCAF II PROFILERBI
7 D.C. 36.2 + 8.8 90.7 + 4.1 1.9 + 1.1 7.4 + 3.140.7 + 8.0 23.1 + 5.7 27.4 + 7.5 9.3 + 0.5
9 N.C. 48.7 + 16.2 89.2 + 8.3 3.4 + 2.6 7.4 + 6.0 5.9 + 1.245.9 + 15.9 5.4 + 3.4 15.7 + 9.4
90.1 + 2.6 2.3 + 1.1 9.2 + 0.59 D.C. 37.9 + 9.6 41.7 + 6.4 20.3 + 6.3 26.3 + 7.0 7.7 + 2.0
63.0 + 15.1 8.9 + 10.6 28.1 + 9.9 6.8 + 0.4S.C. 46.7 + 12.3 49.6 + 12.9 3.8 + 1.6 3.8 + 4.6
48.3 + 15.3 11.2 + 7.6 22.5 + 10.1 89.2 + 10.2 2.5 + 3.0 8.4 + 7.4 8.0 + 0.7NOVO 40.6 + 13.7
23.5 + 6.3 8.1 + 2.9 29.0 + 5.2 89.8 + 6.1 2.8 + 3.0 8.6 + 4.7 8.5 + 0.768.5 + 7.7RE-R
TABLE 5: Data for Experiment #5, means ±_ SD
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EXPERIMENT #5 
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7 D.C. 9 N.C. 9 D.C. S.C. NOVO RE-R
EXPERIMENTAL GROUPS
FIGURE 14: Osteoblast Area Fraction (white bars), Resting Area Fraction 
(striped bars), and Osteoclast Area Fraction (crosshatched bars), means ± 
SEM. Experimental groups: 7 D.C. = 7-day deficient control, 9 N.C. — 9- ay 
normal control, 9 D.C. = 9-day deficient control, S.C. = supplemented 

















7 D.C. 9 N.C. 9 D.C. S.C. NOVO RE-R
EXPERIMENTAL GROUPS
FIGURE 15: Ruffled Border Index, means ± SEM. Experimental groups:
7 D.C. = 7-day deficient control, 9 N.C. = 9-day normal control,
9 D.C. = 9-day deficient control, S.C. = supplemented control,















7 D.C. 9 N.C. 9 D.C. S.C. NOVO RE-R
EXPERIMENTAL GROUPS
FIGURE 16: Osteoclast Contact Index, means ± SEM. Experimental groups:
7 D.C. = 7-day deficient control, 9 N.C. = 9-day normal control,
9 D.C. = 9-day deficient control, S.C. = supplemented control,














7 D.C. 9 N.C. 9 D.C. S.C. NOVO RE-R
EXPERIMENTAL GROUPS
FIGURE 17: Osteoclast Separation Index, means +. SEM. Experimental groups: 
7 D.C. = 7-day deficient control, 9 N.C. = 9-day normal control,
9 D.C. = 9-day deficient control, S.C. = supplemented control,
















7 D.C. 9 N.C. 9 D.C. S.C. NOVO RE-R
EXPERIMENTAL GROUPS
FIGURE 18: Osteoclast Isolation Index, means +. SEM. Experimental groups:
7 D.C. = 7-day deficient control, 9 N.C. = 9-day normal control,
9 D.C. = 9-day deficient control, S.C. = supplemented control,
NOVO = de novo recruitment, RE-R = re-recruitment, n = 6 for all groups.
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To measure the profile width, evenly spaced lines were placed across each 
osteoclast profile perpendicular to the bone surface, and the distance between the 
two points where the line intersected the osteoclast cell boundary was measured. 
The two deficient control groups showed significantly greater osteoclast profile 
widths than all the other groups except the re-recruitment group (Figure 19, page 
78), and while there was not a significant difference between the osteoclast 
profile width of the de novo recruitment and the re-recruitment groups, these two 
groups had greater profile widths than either the normal control or the 
supplemented control groups.
The interesting comparison here is between the de novo recruitment group 
and the re-recruitment group. If re-recruitment does in fact take place following 
two days of calcium-induced inhibition, one would expect the parameters 
indicating increased osteoclastic activity, i.e., OCAF, RBI and Cl, to be greater in 
the re-recruitment group than in the de novo group. Such is not the case here. 
The OCAF is actually greater (though not statistically) in the de novo group, 
while the re-recruitment group shows much greater osteoblast activity and a lower 
resting cell fraction than any of the other groups. What seems to be happening 
here is that, as was shown in a previous study, the osteoblasts are turned on only 
after two days of supplementation. There is evidently a sort of rebound 
phenomenon - the osteoblasts become "hyperactive" at the expense of the resting 
cell fraction. While the OCAF is greater in the re-recruitment group than in the 
normal and supplemented controls, it does not yet approach deficient control 




















7 D.C. 9 N.C. 9 D.C. S.C. NOVO RE-R
EXPERIMENTAL GROUPS
FIGURE 19: Osteoclast Profile Width, means ± SEM. Experimental groups:
7 D.C. = 7-day deficient control, 9 N.C. = 9-day normal control,
9 D.C. = 9-day deficient control, S.C. = supplemented control,
NOVO = de novo recruitment, RE-R = re-recruitment, n = 6 for all groups.
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The supplemented normal control group behaves as would be predicted, with 
osteoblast and osteoclast levels returning to normal control levels after two days 
calcium supplementation. While the de novo group differs significantly from the 
re-recruitment group in the OBAF and RAF, the difference between the de novo 
and the normal control groups in the OCAF only approaches significance, 
indicating that 2 days is not really enough to see the effects of calcium deficiency; 
the OCAFs for the two deficient controls are significantly greater than the OCAF 
for the de novo recruitment group, and the osteoclast profile widths for these two 
groups are also significantly greater than in the de novo group. Though the 
profile width in the re-recruitment group is not statistically different from the de 
novo group, it does show a tendency to approach deficient levels, suggesting that 
while the OCAF has decreased, those osteoclasts that remain still show a
relatively high degree of activation.
DISCUSSION
As was previously discussed, bone metabolism is partly under the control of 
hormones. In addition to PTH, CT, Dj and estrogen, growth hormone (GH) 
influences bone cells. The actions of growth hormone are mediated by a class of 
compounds formerly called somatomedins, and now known as insulin-like growth 
factors (IGF), because of their similarity in structure and function to insulin. The 
IGFs are carried in the blood by several carrier proteins, called IGF binding 
proteins (IGFBPs).
Fasting has been shown to affect the GH/IGF axis. Several studies have 
shown that fasting decreases serum IGF-I (somatomedin-C) levels (Phillips and 
Young 1976; Clemmons et al. 1981; Merimee, Zapf and Froesch 1982; Isley, 
Underwood and Clemmons 1983), as well as extractable hepatic IGF-I (Goldstein, 
Harp and Phillips 1991). This fall in serum IGF-I levels has been shown to 
correlate with a decrease in the number of hepatic GH binding sites (Maes, 
Underwood, and Ketelslegers 1983), and with decreases in T3 and insulin 
production (Caufriez et al. 1984). The decrease in IGF-I appears to be due to a 
decrease in IGF-I mRNA levels with fasting (Emler and Schalch 1987; Lowe et 
al. 1989; Goldstein, Harp and Phillips 1991). Fasting has also been shown to 
decrease IGFBP levels (McCusker et al. 1991).
GH has been shown to affect both bone formation and bone resorption. 
Brixen et al. (1990) injected normal human volunteers twice daily for seven days 
with recombinant human GH, and measured resultant changes in biochemical 
markers for bone formation and resorption. They found that at first both
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formation and resorption increased as measured by changes in urinary 
hydroxyproline/creatinine and calcium/creatinine ratios, and by serum bone Gla 
protein and alkaline phosphatase levels. Within a few weeks, however, resorption 
parameters decreased, but formation parameters remained elevated for long 
periods of time. The authors concluded that GH stimulated osteoblast activity 
and bone remodeling. Similar results were reported by Schlemmer et al. (1991). 
They gave daily injections of synthetic human GH to GH-deficient patients over a 
period of four months. This caused rises in fasting urinary excretion of 
pyridinoline and deoxypyridinoline, two newly discovered markers of bone 
resorption. However, there was also a corresponding increase in plasma bone 
Gla protein, which is a marker of bone formation. These authors also concluded 
that GH injections increase bone remodeling. Hock and Fonesca (1990) showed 
that PTH produced anabolic effects in rat bones only if GH was present. After 
injecting PTH into hypophysectomized (HX) and sham-operated male rats daily 
for 12 days, they found that in the sham animals there was an increase in bone 
calcium, bone dry weight and hydroxyproline, but in HX rats, these anabolic 
parameters were absent Injecting GH with PTH restored the anabolic effects 
produced by PTH. IGF was also shown to stimulate bone formation in calvarial 
cultures (Canalis, 1980; Hock, Centrella and Canalis 1988; Canalis et al. 1989; 
Spencer et al. 1991). linkhart and Mohan (1989) reported that PTH stimulated 
calvarial osteoblasts in culture to release IGF-I and II, which in turn stimulated 
osteoblastic proliferation. They concluded that IGF participated in the coupling 
of formation and resorption.
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Spencer et al. (1991) reported that infusion of IGF-I into the right hindlimb 
of ambulatory rats increased bone formation, but decreased the number of 
osteoclasts, leading them to conclude that IGF-I is purely anabolic in its actions. 
However, Slootweg et al. (1992) reported that adding IGF-I to fetal mouse 
radii/ulnae cultures containing mature osteoclasts did not produce a response, but 
when IGF-I was added to metacarpal/metatarsal cultures containing osteoclast 
precursor cells, the number of osteoclasts increased, and bone resorption also 
increased. They concluded that IGF-I has a stimulatory effect on osteoclast 
precursors but not on mature osteoclasts.
These studies could provide clues about how fasting brings about the changes 
that were observed in these experiments. The fasting experiments in this study 
have provided several pieces of information. First, it was shown that short-term 
fasting can reverse osteoclast recession induced by calcium supplementation in 
calcium-deficient rats. Second, it was found that when normal rats are fasted for 
48 hours, the OBAF decreases dramatically concomitantly with an increase in the 
RAF. This apparent reduction in osteoblast activity might be explained in part 
on the basis of a reduction in GH and IGF activity, since some of the above 
studies show that GH and IGF-I stimulate osteoblastic activity and bone 
formation. The reduction in IGF-I might also explain the reason why, in spite of 
the presumed decrease in blood calcium levels with fasting, the OCAF did not 
increase in the fasting animals, since as Slootweg et al. (1992) demonstrated, IGF- 
I has a stimulatory effect on osteoclast precursors. Additionally, osteoblasts are
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known to secrete factors such as IL-1 and IL-6 that stimulate osteoclast activity. 
A reduction in osteoblast activity might also contribute in this way to a reduction
in the OCAF.
The results of this study have confirmed that while a calcium-deficient diet is 
capable of recruiting large numbers of osteoclasts to rat tibial diaphyses, feeding 
deficient animals a calcium-containing diet for 12-48 hours causes osteoclasts to 
recede from bone. It was shown that osteoclast recession is a graded process, and 
that a 12-hour fasting period can reverse the effects of 12 hours of calcium 
supplementation on osteoclast morphology. The fast presumably lowers plasma 
calcium levels, which would cause a decrease in calcitonin levels and an increase 
in levels of PTH. Either of these factors, or a combination of both, could 
account for the reactivation of inhibited osteoclasts due to fasting.
While 48 hours of calcium deficiency in normal rats has been shown to be 
sufficient to significantly increase the osteoclast area fraction of the tibial 
endosteum at the expense of the RAF, 48 hours of fasting in normal rats 
increases the resting area fraction of the endosteum while decreasing the 
osteoblast area fraction. Thus, short-term fasting operates by reducing bone 
formation rather than by increasing bone resorption. It must be noted that the 
action of fasting on bone is probably much more complex than simply causing a 
reduction in blood calcium. As was pointed out earlier, fasting produces many 
effects in the body, including changes in carbohydrate, lipid and protein 
metabolism. The effects of these changes on bone cells is not known.
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Finally, this study has shown that if inhibited osteoclasts can be re-recruited 
to bone, it apparently takes longer than 48 hours of calcium deficiency to bring 
the osteoclasts back to pre-inhibition levels of activity.
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EXPERIMENT #1; DEFICIENT CONTROL
Animal M ORAF PAP nr af PRI ri ci XL RF.M
5 21.6 51.2 27.2 19.7 80.9 7.7 0.711.4
18.81 2 58.4 22.9 17.2 88.0 4.3 7.7 1.6
9.51 8 49.1 41.4 24.0 88.7 2.3 9.0 0.7
2 3 22.1 52.2 25.8 24.6 88.0 3.5 8.5 0.0
5.83 1 9.4 41.7 48.9 16.0 94.0 0.2 0.1
3 8 32.5 40.0 27.4 13.5 87.8 3.6 0.78.6
MEAN 19.0 483 323 193 87.9 43 7.9 0.6
SD 8.0 63 93 4.1 33 33 1.0 03
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EXPERIMENT #1: 3.HOUR SUPPLEMENTED
ORAF XL PFMAnimal M RAF HTAF RRI ri SL
5.8 0.223.9 56.9 19.2 25.4 89.8 4.41
E DE C E S8 D A
8.425.7 86.9 4.7 0.09 11.2 63.1 19.6
11.229.9 56.8 133 27.4 82.8 5.9 0.02 5
0.018.5 50.1 31.4 27.8 903 5.0 4.63 2
8342.1 90.4 0.438.7 19.2 12.0 1.14 1
7.4MEAN 25.1 53.1 2L8 22.4 88.1 43 0.1
23 02SD 11.7 93 6.7 33 2.06.9
EXPERIMENT #1: 6-HOUR SUPPLEMENTED
PFMXL31riRAF nrAF -RELr>RAFAnimal
1.25.4 7.218.2 87.358.8 31.39.91 6
0.34.31.221.8 19.7 94.646.7 31.52 0
9.8 0.05.923.0 84.327.730.92 1 41.4
035.60.345.0 25.7 26.4 94.129.32 2
0.00.7 5.112.9 94.248.115.8 36.13 4
0.15.6 9.684.827.5 13.842.130.44 2
036389.9 33MEAN 273 42.5 19.030.4
23 0.52.743SO 53123 93 93
89
EXPERIMENT #1: 9-HOUR SUPPLEMENTED
XL R£M.n SLPAF nr af PRIAnimal £ ORAF
9.6 2.074.2 16.247.7 38.9 1.713.42
0.38.5 6.38.9 85.224.4 51.2 24.43
7.5 5.9 0.99.0 86.615.1 58.4 26.46
0.00.7 6.952.1 18.7 92.424.8 23.22 4
4.7 0.357.8 15.2 18.3 91.2 4.127.02 9
4.5 5.0 0.390.428.8 48.9 22.3 14.93 0
6.9 6.4 0.686.722.3 52.7 25.1 115MEAN
4.9 1.6 0.77.1 6.0 6.1SD 5.9 4.1
EXPERIMENT #1: 12-HOUR SUPPLEMENTED
n PFMnrAF J£BL jCL SInRAF PAFAnimal M-
1.05.4 3.367.6 20.3 16.5 91.37 12.0
93.5 4.3 2.2 0.020.8 23.532.8 46.41 0
3.6 5.0 0.116.8 91.418.2 68.0 13.81 1
0.191.0 2.2 6.77.8 67.9 24.3 1832 6
0.0943 2.7 2.824.7 47.3 28.0 17.73 6
0.5913 0.9 7.637.2 20.6 4.93 7 42.2
03922 32 4.6MEAN 22.1 213 16356.6
0.41.6 22SD 4.7 6.1 1.411.6 12.5
90
EXPERIMENT #1: TOTAL SUPPLEMENTED
.REM.si IIPRI Jdor af RAFAnimal $
0.095.5 1.5 3.012.715.3 57.7 27.14
9.4 0.352.2 19.4 73.0 17.627.9 20.01 3
5.9 0.020.2 21.0 91.0 3.117.8 62.01 4
94.4 0.7 4.853.3 30.3 0.13 5 16.4 11.1
0.31.5 79.4 3.8 16.820.2 54.7 25.23 9
2.5 8.2 0.011.3 89.445.8 31.3 22.94 0
7.7 0.1231L5 89.9MEAN 23.1 5L8 25.1
0.14.85.73.5 62 1.1SD 11.5 10.7
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EXPERIMENT #2: NORMAL CONTROL
PPMIIri siRAF nrA.v PRIAnimal nRAF
5.0 0.095.0 0.070.7 6.6 4.522.63
0.094.2 5.838.5 0.029.7 65.9 4.44
21.2 0.0272 78.8 0.060.4 36.6 3.06
15.5 0.042.6 52.0 5.8 5.7 77.0 7.41 7
49.5 4.5 103 0.0383 12.8 24.4 85.21 9
42.7 503 8.5 2.5 17.2 18.9 0.02 0 63.9
MEAN 543 123 0.039.4 63 17.1 82.4 4.9
SD 13.0 123 33 11.7 63 63 0.014.9
EXPERIMENT #2; DEFICIENT CONTROL
PPM11Jd SInr af PRIr>RAP PAPAnimal it
0.210.42.5193 87.155.7 37.0831 1
0.010.43.528.7 86.124.029.0 47.91 6
0.011.7783 10.013.5 12.0313 5631 8
0.011.24.784.1423 43.7 19316.02 2
0.010.289.7 0.12 3 24.9 473 27.8 31.1
0.015.029.6 81.6 3.42 4 35.1 24.541.2
0.011.5MEAN 4.048.5 28.4 23.4 84.524.1
13 0.1SD 337.6 4.110.1 63 10.6
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EXPERIMENT #2: FASTING SUPPLEMENTED









EXPERIMENT #2i NON-FASTING SUPPLEMENTED
Animal M nRAP PAP nr af PRI ri SL ii REM
2 26.0 59.0 17.6 11.7 68.4 14.7 0.416.9
8 29.8 62.1 9.5 83 69.6 15.1 153 0.0
9 19.7 64.0 17.6 4.4 682 7.6 242 0.0
1 2 29.8 56.0 16.7 9.6 60.1 15.1 24.9 0.0
1 4 183 73.1 10.7 93 553 21.1 23.6 0.0
2 1 27.9 563 18.0 7.6 60.1 12.4 273 0.1
MEAN 253 613 15.0 83 63.6 143 0.122.1
SD 5.0 6.4 33 2.4 53 4.4 43 02
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EXPERIMENT #3: RESTRICTED SUPPLEMENTED
J1 RKMri siPRIRAF OPAFORAFA n i irm I #
2.4 12.2 0.085.316.2 16.123 61.25
13.7 0.081 5.351.3 14.8 16.434.78
0.027.1 16.7 2.6 1483.455.318.39
28.3 0.070 1.817.2 7.820.1 63.11 3
0.022.920.7 6.9 76.1 1.057.721.81 5
0.017.777.4 4.922.6 18.151.626.91 7
18.1 0.013.7 78.9 3.019.856.7MEAN 24.1
0.01.7 635.64.6 4.95.9 4.9SD
EXPERIMENT #3; 12-HOUR AD LIB
PFMM■CL SLAnimal $ nRAF RAF nrAF PRI
0.07.5 22370.221.0 70.3 9.4 1.91
293 0.03.97.3 773 15.9 1.5 66.82
0.032.23.5 5.713.8 74.1 12.9 62.13
0.062.5 5.0 32.631.0 58.0 11.5 4.26
0.023.10.77 37.9 55.1 7.0 6.1 762
0.070.2 3.3 31.01 1 16.1 14.2 2.6 65.6
0.0MEAN 28.4213 673 673 4.411.8 33
SD 0.04.611.4 83 33 1.7 53 23
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EXPERIMENT #3; 24-HOUR AD LIB
HFMIIPR1 PIPAF nrAFr>RAFAnimal #
0.022.177.7 0.217.28.524.9 66.64
25.1 0.05.969.06.262.0 8.130.40
44.7 0.047.9 7.44.5 0.035.0 60.81 2
0.024.475.6 0.07.1 12.437.9 55.01 4
0.016.10.85.2 83.029.5 61.6 8.91 6
0.023.773.1 3.257.5 6.4 10.036.41 8
0.026.0MEAN 2.932.4 60.6 7J 8.5 71.1
9.7 0.0SD 12J 3.14.9 4.0 1.6 6.0
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EXPERIMENT #4; 48.HOUR FASTED
Animal $ OR AF RAF otvaf PRI ri ci II PFM
1 13.4 73.5 13.2 49.2 93.7 0.3 6.0 0.0
8 11.5 74.5 14.1 233 96.2 0.8 3.1 0.0
32.21 0 61.9 6.0 19.0 92.0 1.8 6.2 0.0
1 1 22.1 68.2 9.7 20.8 95.7 0.0 4.3 0.0
1 9 8.8 893 1.9 0.0 82.2 3.5 0.014.3
2 3 18.1 75.0 6.9 38.3 96.0 0.0 4.0 0.0
MEAN 17.7 73.7 8.6 25.1 92.6 631.1 0.0
SD 8.6 9.1 4.6 17.0 5.4 1.4 4.1 0.0
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EXPERIMENT #4: 24-HOUR DEFICIENT
RFMSI IIOR A F RAF OOAF PRlAnimal M.
15.8 20.2 32.7 97.6 0.2 2.2 0.064.02
84.6 8.0 7.5 0.053.2 38.7 8.8 6.57
0.0 7.9 0.050.4 8.4 22.1 92.19 41.2
0.072.7 24.9 98.2 0.0 1.81 3 2.4 24.3
0.01 7 57.0 37.3 5.7 9.6 97.8 0.8 1.3
56.7 15.0 0.01 8 28.3 25.6 91.0 9.0 0.0
MEAN 51.0 1.5 5.039.1 10.1 20.1 93.6 0.0
SD 18.9 13.8 5.4 3J 3.5 0.06^ 10.1
EXPERIMENT #4; 48-HOUR DEFICIENT
PRI PFMIISLXIPAF nrAFnRAFAnimal #
0.09.71.228.5 89.243.5 13.043.73
7.7 0.00.85.1 91.532.2 24.643.45
0.013.412.174.639.5 3.948.6 13.66
0.5 0.00.099.510.132.9 57.9 9.21 2
4.1 0.00.095.926.247.4 28.723.92 1
0.03.70.096.314.5 26.640.9 44.62 4
6.5 0.02.416.7 91JMEAN 44.2 17-338.9
4.7 0.08.9 4.811.6SD 8.5 7.69.0
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EXPERIMENT #5: 7-DAY DEFICIENT CONTROL
ClAnimal 4 OBAF REM PROFRAF OCAF RBI SI II
NO6 21.6 56.3 22.2 18.1 90.3 0.01.8 8.0
10 39.3 19.4 84.9 3.6 0.038.0 22.7 11.5 9.5
32.927 26.8 25.8 89.0 0.140.3 1.6 9.4 8.6
33 45.9 36.1 33.3 93.9 0.018.1 1.2 4.9 9.9
33.834 34.1 32.2 32.3 96.6 0.00.6 2.8 9.5
35 43.7 35.6 89.439.6 16.7 2.7 7.9 0.0 9.1
MEAN 36.2 23.1 27.4 90.7 0.040.7 1.9 9.37.4
SD 8.8 0.08.0 5.7 7.5 4.1 0.51.1 3.1
EXPERIMENT #5: 9-DAY NORMAL CONTROL
OBAFAnimal # RAF OCAF ClRBI SI II REM PROF
1 51.2 43.7 84.45.1 10.6 6.1 NO9.5 0.0
32.5 65.94 1.6 9.3 98.3 1.7 0.0 NO0.0
30.460.47 9.2 33.1 78.6 6.1 15.3 0.0 NO
39.017 54.2 6.8 9.5 91.5 1.8 6.7 0.0 7.1
73.819 24.9 1.3 11.7 84.0 4.5 11.5 0.0 4.7
22 35.1 56.4 8.5 20.0 98.8 0.0 1.2 0.0 5.9
MEAN 48.7 45.9 89.25.4 15.7 3.4 0.07.4 5.9
SO 16.2 8.315.9 3.4 9.4 2.6 1.26.0 0.0
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EXPERIMENT #5: 9-DAY DEFICIENT CONTROL
PROFSICl II REMOCAF RBIOBAF RAFAnimal #
NO0.01.293.2 5.713.0 39.040.946.05
NO1.8 0.091.1 7.123.722.939.6 37.49
8.50.090.0 1.6 8.419.9 20.727.8 52.321
9.185.8 4.2 10.0 0.021.7 29.535.443.023
9.00.01.7 9.888.521.046.2 29.524.426
10.10.091.7 3.0 5.315.5 23.937.746.828
9.20.02.3 7.790.126.320.337.9 41.7MEAN
0.50.02.02.6 1.16.3 7.06.49.6SO
EXPERIMENT #5: SUPPLEMENTED CONTROL
Animal 4 OBAF RAF OCAF RBI Cl SI II REM PROF
3 63.1 33.9 3.0 0.0 42.2 30.1 27.7 0.0 NO
14 50.8 42.7 6.6 4.7 63.8 6.6 29.7 0.0 7.1
15 53.2 42.0 4.8 7.4 55.9 3.7 40.3 0.0 6.9
20 42.0 54.8 3.1 10.8 87.8 1.2 11.0 0.0 6.7
29 26.6 70.4 3.0 0.0 60.2 5.3 34.5 0.0 7.1
30 44.3 53.6 2.1 0.0 68.2 6.4 25.5 0.0 6.2
MEAN 46.7 49.6 3.8 3.8 63.0 8.9 28.1 0.0 6.8
SO 12.3 12.9 1.6 4.6 15.1 10.6 9.9 0.0 0.4
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EXPERIMENT #5: DE NOVO RECRUITMENT
PROFSIOCAF Cl II REMRAF RBIAnimal H OBAF
ND4.0 13.8 0.038.1 82.245.3 16.7 34.92
9.2 8.423.0 90.1 0.7 0.042.4 25.534.611
7.930.0 7.2 72.2 19.9 6.913.6 0.012 62.8
53.6 0.7 2.83.6 7.3 96.5 0.0 8.316 42.8
51.6 12.2 27.9 97.9 0.6 1.5 0.0 8.531 36.2
73.9 4.5 26.0 96.2 1.0 2.9 0.021.6 7.732
48.3 89.2 2.5 8.4 8.011.2 22.5 0.0MEAN 40.6
3.0SD 15.3 7.6 10.2 7.4 0.0 0.710.113.7
EXPERIMENT #5: RE-RECRUITMENT
Animal U OBAF RAF OCAF RBI Cl SI II REM PROF
8 71.7 18.4 10.0 36.5 86.7 2.1 11.1 0.0 NO
13 64.9 23.6 11.6 31.3 87.1 1.6 11.2 0.0 9.0
18 64.2 30.0 5.8 23.9 91.2 0.6 8.1 0.0 8.1
24 58.5 31.3 10.2 27.6 81.4 4.6 14.0 0.0 9.0
25 80.7 15.4 4.0 31.6 99.1 0.0 0.9 0.0 8.9
36 70.7 22.1 7.2 23.0 93.2 0.8 6.0 0.0 7.4
MEAN 68.5 23.5 8.1 29.0 89.8 2.8 8.6 0.0 8.5
SD 6.37.7 2.9 5.2 6.1 3.0 4.7 0.0 0.7
APPENDIX C
RESTING CELLS - layer of very flat cells covering the bone
OSTEOBLASTS - the layer of large cells covering the bone
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OSTEOCLAST - large, multinucleated cell lying on the bone 
surface. Note the ruffled border adjacent to the bone.
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